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INTRODUCTION 
Among endocrine disorder in pregnancy thyroid dysfunction is the 
second most common. Pregnancy increases the demand on maternal 
thyroid gland. Thyroid dysfunction has an adverse maternal and fetal 
effects 
Among thyroid dysfunction ,hypothyroid has a relatively high 
prevalence  during pregnancy affecting  upto 14.3 % of all pregnant 
women in India. (dhanwal et al) 
Hypothyroidism can be  clinical/overt and subclinical . 
Clinical hypothyroidism defined as elevated serum level of thyroid 
stimulating hormones (TSH >10 miu/l)and subnormal free thyroxine 
level. 
Sub clinical hypothyroid defined as enchanced TSH level, usually 
beyond the upper reference limit and a normal  fT4 level.  
Hypothyroidism can be primary and central 
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Primary hypothyroidism mainly caused by a primary abnormality 
in the thyroid.  
Central hypothyroidism-5% due to lack of TSH and its effects. 
T3,T4,fT4 were done to diagnose central hypothyroidism. 
Subclinical Hypothyroidism: 
Subclinical hypothyroidism defined as enhanced  value of Serum 
TSH  according to the trimester specific reference and normal free T 4. 
Incidence of subclinical hypothyroidism is 2.5% in western 
countries. (vary with ethinicity) 
SCH mostly asymptomatic, but there is evidence of autoimmune 
thyroid disease (positive TPOAbs and or TGantibodies)in 50-60% (12) 
Subclinical hypothyroidism was  most  frequently seen in women 
delivering  very preterm baby. (before 32 weeks).(12) 
Women with Subclinical hypothyroidism  had a 3 fold increased 
risk of placental abruption and 2 fold increased risk of preterm labour 
compared to euthyroid women.(22) Gestational hypertension also more 
frequently occurred .(23) 
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Enhanced maternal TSH (high level of normal) without decreased 
Thyroid hormone is associated with neonatal respiratory distress, 
miscarriage and preterm delivery (12). 
The likelihood of patients diagnosed as hypothyroids during 
pregnancy to continue to be hypothyroid even after pregnancy depends on 
the initial TSH value. 
The United States Preventive Services Task force reported that 
nearly almost all patients with an initial TSH >5 mIU/ml developed overt 
hypothyroidism within 5 years.(33) 
PROBABLE CAUSES OF SCH in pregnant women 
Chronic/subacute autoimmune thyroiditis (Hashimoto's thyroiditis 
is the major cause of SCH in high income countries and it increases with 
age) 
Iodine deficiency 
Radioactive iodine therapy 
Surgical removal of thyroid gland.  
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Drugs like  
lithium,  
Amiodarone,  
Interferon alpha,  
Interlukin 2,  
Rifampicin, 
 Sunitinib and  
Thalidomide. 
Presence of goitrogens in diet in India 
Risk factors: 
Type 1 DM 
Autoimmune disease 
Family history of hypothyroid 
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Pathogenesis 
At molecular level, thyroid hormone has role in placenta 
development. 
In hypothyroidism early faulty development of placenta due to 
decreased level of thyroid hormones leads to  miscarriage, preeclampsia, 
abruption and preterm labour. Thyroid hormone synthesis require 
adequate amount of iodine. Severe deficiency of iodine causes 
hypothyroidism. It found to be associated with decreased intelligence, 
cretinism and even congenital anomalies of the fetus. 
Intra uterine growth restriction and fetal distress are more common 
in women with subclinical hypothyroidism. 
Complications of subclinical hypothyroidism in pregnancy can be 
prevented if thyroxine treatment is started in 1
st
 trimester (ideally 
antenatally). 
Treatment after 1st trimester will not eliminate already established 
fetal neurodevelopmental delay, because it is in the first trimester that the 
fetus depends completely on maternal thyroid hormone for brain 
development. 
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Thyroid function tests-should cautiously interpreted during 
pregnancy due to physiological changes of thyroid. The cutoff values for 
diagnosing thyroid dysfunction in pregnant women is not the same as non 
pregnant women. The diagnosis of hypothyroidism is also difficult in 
pregnancy because many of the symptoms and signs of hypothyroidism 
resembles pregnancy symptoms. 
Severe clinical/overt hypothyroidism rarely becomes pregnant  
because most of these women will be infertile and they also have higher 
rates of miscarriages. 
There are not enough studies in pregnant women with 
hypothyroidism to see if early thyroxine supplementation and adequate 
treatment actually reduces the occurrence of complications. This study 
was undertaken to identify prevalence maternal and fetal outcomes, find 
if promptly diagnosed and adequately treated hypothyroid women were 
able to avert complications. 
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REVIEW OF LITERATURE 
Prevalence of subclinical hypothyroidism in pregnancy * 2014 
European Thyroid Association reported - prevalence of subclinical 
hypothyroid in pregnancy is 2 -2.5% in west. *China-4% *Belgium-6.8%                                                                                             
*North Spain as high as 13.7%.  
Endocrine society guidelines studied data from 523 healthy 
pregnant women with no known history of  thyroid disorder. In this group 
65 women (12%) had subclinical hypothyroidism. 
 Liang  Miao chen et al 2014 conducted prospective study of data 
from 8012 women in pregnant.371 women were SCH,7641 euthyroid. 
The results of this study was increased risk of GH,PROM  and infants had 
increased risk of  IUGR, LBW. Thus routine maternal thyroid functioning 
testing is needed  to improve the maternal and fetal outcomes. 
INDIAN  
In 2013 Dhanwal D K et al reported  prevalence of sub clinical 
hypothyroidism during 1
st
 trimester was high -135/143 (North India 
14.3%).  
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In 2006 Rao et al studied 163 non pregnant women with recurrent 
pregnancy  loss in gestational  age 12 wks in Hyderabad. This study  was  
detected 4.2% prevalence of  subclinical hypothyroidism. In 2007 two 
government obstetrics and gynecology hospital  in Chennai   conducted 
study in prevalence of hypothyroid in pregnancy –the study reported 
subclinical hypothyroidism was  2.8% . 
In 2010 Sahu et al reported that prevalence of subclinical 
hypothyroid in pregnancy was 6.47%  by  this  prospective analysis of 2
nd
  
trimester TSH level in 633 pregnant women. If TSH level was sub normal 
then free T4 and TPO Ab level were done. Patients were carefully 
monitored  till delivery. Their obstetrical and perinatal outcomes were 
analysed. This study concluded increased adverse maternal and fetal 
outcomes. (cesarean section rate for fetal distress was high) 
Vaidya et al  5 yr followup for 523pregnant  women with no 
known thyroid disorder. TFT was done during antenatal period. In this 
study reported 12.4% of women was subclinical hypothyroidism in 
pregnancy.  
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In 2015 Rao S et al this study was conducted in ESI hospital, 
Hyderabad.1062 pregnant women included and TFT done in routine 
antenatal clinic. He was reported 14.3% subclinical hypothyroidism and 
6.2% overt hypothyroidism.                                                            
Nidhi Jalida Tinku et al 2014 this cross sectional study conducted 
in Bangalore. It includes 334 pregnant women of <14 wks gestation. This 
study was conducted in the urban population of southern India had 
adequate iodine status inspite this adequate iodine status  prevalence of  
9.2%  subclinical hypothyroidism and3.7% overt hypothyroidism. 
SCREENING 
Universal screening VS Targeted case finding  
Vaidya et al reported that screening consider only women with  
high risk would miss 30%, so this study suggested that universal 
screening.  
Dhanwal d k et al study in  north india  concludes that there is high 
prevalence of hypothyroidism 14.3% (135/143), majority being 
subclinical hypothyroidism, from   this  inferences, reported universal 
screening of  hypothyroidism may be useful in our country. 
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Negro et al study  not  suggested   universal screening- This study  
includes two groups – One is universal screening group consist of 484 
women in high risk, 1798women  low risk, another group is targeted case 
finding  group consist of  454 women in high risk and 1828 low risk.  
This study  did not show any statistically significant reduction in 
adverse out comes with low risk women treatment with L Thyroxine  in  
universal screening group. 
According to ACOG SCH  prevalence  was 2 - 5%.This guidelines 
states that benefit of treatment to either mother and fetus has not yet been 
demonstrated &routine screening for subclinical hypothyroidism in 
pregnant women is not currently recommended. 
ADVERSE MATERNAL AND FETAL OUTCOMES: 
In 1998, Leung AS et al  study conducted in Losangeles. here ,68 
hypothyroid patients with no other medical disorders were analysed .23 
women with OH  and 45 Women with SCH They were  identified  the 
adverse maternal outcomes of–pre eclampsia 22.5% OH/7.6%, 
gestational hypertension  36 % OH /25 %SCH. No adverse fetal and 
neonatal outcomes. 
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Wilson KL, Casey BM et al from November  2000 through April 
2003- 24883 pregnant women were analysed for pregnancy hypertension 
.Results showed that 10.9% pregnancy hypertension was subclinical 
hypothyroidism group. This analysis concluded women  with subclinical 
hypothyroidism identified during pregnancy have an increased risk for 
severe preeclampsia when compared with euthyroid. 
               Vander zanden et al showed that subclinical hypothyroidism 
women prone to get vascular complication of about 19.6% (hypertension 
during  pregnancy) In the best study to date, Negro and colleagues  
suggested SCH increases the risk Maternal and fetal side effects.  
Rajat  Mohanty et al 2014 study concluded prevalence of 
subclinical hypothyroidism  in south asia especially in India is more than 
other parts of world and mostly due to autoimmune and nutrition 
deficiency. The complications like abortion, preterm birth ,poor birth 
weight ,hypertension of pregnancy and convert to overt hypothyroidism. 
Tudela CM et al conducted in study from November  2000 to April 
2003 to estimate relation ship between sub clincal hypothyroidism and 
gestational diabetes about 24883 women.  
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Results showed that 23771 were euthyroid and 528 [2%] 
subclinical hypothyroidism. There was  increased risk of GDM from 
1.9% to4.9%as thyrotropin increased from 0.001 to 10 milliunits/l. This 
study supports relation between subclinical hypothyroid and diabetes 
during pregnancy. 
Jacmshid vafaeimanesh et al in 2011-2012  screened about 210 
pregnant women (105 -with and 105without GDM) suggested screening  
and treatment of subclinical hypothyroid in GDM. In GDM  had 17.1% 
SCH/7 EH and in non GDM 7SCH/4EH.    
Liang miao chen colleagues conducted study in china 2014, 8012 
pregnant women included out this 371 was SCH, 7641was  euthyroid. 
Risk associated with SCH were GHTN-3.5SCH/1.8% EH, PROM 
4.9%SCH/8.6% EH, IUGR 1.008% SCH /2.9 % EHand LBW 
1.8%SCH/4.5%EH. 
          J clin endocrinol metab oct 2011 concluded that subclinical 
hypothyroidism was associated with increase risk of fetal distress, 
preterm labour and neurodevelopmental delay. 
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 Abalovich et al showed that untreated hypothyroidism, subclinical 
hypothyroidism, clinical hypothyroidism at the time of conception is 
associated with miscarriage rate of 31.4%compared with 4% in euthyroid 
at conception of pregnancy complication like preterm labour, RDS, NICU 
care. 
TPO Ab 
Taka  Mastu et al study conducted in 437 patients, found   both 
types of auto  anti bodies TPO Ab and Tg positive in 316,only one in 85 
and none in 36 .Among patients positive for autoantibodies 50-70% were 
euthyroid, 25-  50%have subclinical and 5-10% clinical hypothyroidism. 
In 2010 the study was conducted by De vivo A et al 216 pregnant 
women were enrolled. 176 women were euthyroid, 24 pts were found to 
have positive auto antibodies, 8 women were sub clinical 
hypothyroidism. women with subclinical hypothyroidism had 
significantly  more risk for early pregnancy loss (p-0.02) 
TREATMENT 
 Should subclinical hypothyroidism be treated in pregnancy.                            
ACOG 2010 –No ATA  2011 -  yes Endocrine society  2012  - yes 
Endocrine society suggested L Thyroxine treatment for all pregnant 
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women with subclinical hypothyroidism irrespective of TPO Ab. 
American thyroid association also suggested  L thyroxine for pregnant 
women with subclinical hypothyroidism and positive  TPO Ab.                                                      
 European endocrinologist also suggested  L thyroxine for 
subclinical hypothyroidism.  
Bverley m shield et al 2013  conducted study in U K 523 women. 
In this study L thyroxine  was given in all pregnant women with 
subclinical hypothyroidism  and most case of subclinical hypothyroidism 
was resolved in postdelivery.so no need to continue L thyroxine post 
delivery. 
PHYSIOLOGY OF THYROID 
Iodine metabolism and increased Iodine requirement in pregnancy: 
The average daily iodine requirement is 0.1mg.  
Sources of iodine 
Fish, milk, eggs and iodised salt are rich sources of iodine. 
Absorption of iodine. 
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In the stomach and jejunum iodine is rapidly converted to iodide 
and absorbed into the blood stream. 
Metabolism of  Iodine: 
Iodide actively enters the thyroid follicular cells by an ATP 
dependent process. Thyroid stores nearly 90% of body’s iodine. The 
excess plasma iodine is excreted through the kidneys. 
Thyroid hormone synthesis, secretion and transport: 
The thyroid gland secretes two main hormones, Thyroxine  T4 and 
Tri iodothyronine T3. T4 is produced in greater quantities than T3 (at a 
rate of 10:1) but T3 is the major biologically active thyroid hormone and 
is mostly derived from T4 in the peripheral tissue. 
Iodine is obtained from the diet, converted to iodide, actively 
transported into the thyroid. 
The are 5 steps in the production of thyroid hormones 
1) Iodide trapping- iodide incorporated into the thyroglobulin by the 
way  of  the enzyme TPO. It is an ATP dependent active transport 
across the basement membrane of the thyroid follicular cells. The 
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thyroid follicles contain thyroglobulin (Tg) which is a glycoprotein 
with four tyrosyl residues. 
2)  OXIDATION -iodide oxidation to iodine followed by iodination of 
tyrosyl residues on the thyroglobulin. Both the step processes are 
catalysed by thyroid peroxidase. The end products of the second 
step are mono and diiodotyrosine. (MIT&DIT). 
3)  Coupling to form tetraiodothyronine (T4) or one monoiodotyrosine 
and one diiodotyrosine molecule to form triiodothyronine (T3) or 
reverse triiodothyronine (rT3).  
4) Hydrolysis of the thyroglobulin molecule to release free 
iodothyronines (T3andT4) and mono and diiodotyrosines. 
5)  Deiodination  it yielding iodide which is reused by the thyrocyte. 
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MECHANISM OF THYROID SYNTHESIS 
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TRANSPORT   AND  STORAGE 
Thyroid hormones are avidly bound to plasma proteins- only 0.03-
0.08% of T4 and 0.2-0.5%of T3 are in the freeform. Thyroid hormone 
contain most of the protein bound iodine.T4 contain 90-95% PBI. The 
normal concentration of PBI is 4-10ug/dl. only 0.1-0.2% of this inT3,rest 
in T4. 
Thyroid hormones are transported in serum bound form.T4 binds 
to 3 plasma protein in the following decreasing order of avidity.  
1. Thyroxine binding globulin (TBG), 
2.  thyroxine binding prealbumin (TPBA -transthyretin) and 
3.  albumin. 
Free form of thyroid hormone was small and is physiologically active 
hormone. T3 is three to four times more potent than T4. T3 is lower level 
in circulation than T4 and is less tightly bound to proteins. Hence it enters 
tissues more easily. T3 has a half life of one day while T4 has a half life 
of seven days. 
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Thyroid gland release thyroid hormone in the form of T4 is 80%and  
in the form of T3 20%in euthyroid state. 
 
H-P-T AXIS 
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H-P-T axis 
Thyroid hormone production controlled by anterior pituitary by 
TSH-thyrptrophin.  
TSH comprises two subunits and first one alpha subunit in 
common with LH, FSH and hCG and one specific beta subunit. TSH 
shows circadian and pulsatory secretion its secretion peaks at around 
midnight and declines during the day. The function of the pituitary is 
controlled by hypothalamus which secretes TRH .It accelerates the 
production of TSH whereas dopamine and somatostatin hinder it. 
The thyroid hormones have a negative feedback effect on the 
pituitary and hypothalamus which is modified by the concentration in the 
serum and conversion of T4 to T3 locally in brain. Therefore, if T4 
concentration in the serum drops, the inhibitory stimulus is decreased due 
to a diminished local effect of T3 in the pituitary and TSH levels rise to 
stimulate the thyroid gland (ganong 2005, Hadley & Levine 2007) 
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Metabolism and excretion of thyroid hormone: 
T4 and T3 metabolic inactivation occured by glucuronide/sulfate 
conjugation and deiodination in Liver is the primary site, other sites are 
salivary glands and kidneys  The conjugates are excreted in bile. A major 
fraction is deconjugated in the intestines ,re absorbed by entero hepatic 
circulation and excreted in urine. 
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Mechanism of action: 
Two form of thyroid hormone –T4 &T3 penetrates the cells by 
active transport  and combines with a nuclear receptor .TR is bound to 
TRE in the enchancer region of target gene along with corepressors this 
leads to suppression of gene transcription. When T3 binds to TR 
,conformation changes occurred in TR  and releasing the corepressors and 
binding the coactivator, then it induces gene transcription leads to 
production of specific m RNA  and a specific protein.  
Tachycardia, hypertension, arrhythmias, tremor, hyperglycaemia 
are clinical manifestations of thyroid hormone and are mediated partly if 
not completely by sensitisation of adrenergic receptors to catecholamines. 
Functions of thyroid hormones: 
By the process diffusion  thyroid hormones enter the cells  and 
binding of thyroid hormones to the nuclear receptors of cells results in 
translation and transcription of hormone specific genes. They  affect 
almost every system in the body. 
TH play a major  role in fetal brain and skeletal development. 
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Growth and development 
We understood TH action in growth and development  by its action 
on the metamorphosis of tadpole to frog. Its action cannot be labelled 
catabolic or anabolic. 
It exerts a critical control over protein synthesis. Deficiency of 
thyroid hormone mainly affects the nervous system in early life. In 
cretinism there is retardation and nervous deficit as a result of paucity of 
synapse formation axonal and dendritic ramification and reduced 
myelination. In pregnant with subclinical hypothyroidism also 
impairment of intelligence and slowing of movements in the offspring. 
(limited evidence) 
Intermediary metabolism: 
Thyroid hormones have an important role in carbohydrate, lipid 
and protein metabolism.it acts on cell membrane.T4 has role in 
intermediary action. 
Carbohydrate 
It increases BMR  
It increase the  utilisation of carbohydrates  due to the effect of  
increase  BMR, gluconeogenesis and glycogenolysis compensate for it. 
So hyperglycaemia and a diabetic like state occur in hyperthyroidism. 
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Protein: 
T4 has catabolic role overall. Negative nitrogen balance and tissue 
wasting result from prolonged action, it leads to  weight loss in 
hyperthyroidism and weight gain in hypothyroidism. Thyroid hormones 
inhibit mucoprotein synthesis in low concentrations which 
characteristically accumulates in myxedema. 
Lipid: 
T4 and T3 indirectly enhance lipolysis by suppressing a 
phosphodiesterase although lipogenesis is also stimulated. 
Cholesterol metabolism is accelerated but its conversion to bile 
acids dominate. Thus hypocholesterolemia is a feature of 
hyperthyroidism and hypercholesterolemia and obesity are features of 
hypothyroidism. 
Calorigenesis: 
Basal metabolic rate is increased by stimulation of cellular 
metabolism and resetting of the energy stat. But the metabolic rate in 
uterus, gonads, brain, spleen and lymph nodes is not significantly 
affected. The mechanism is uncoupling of oxidative phosphorylation thus 
releasing excess energy as heat. 
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Cardio vascular system 
T4 and T3 causes hyperdynamic state. 
Heart rate, contractility and output are increased which cause a fast 
and bounding pulse. Thyroid hormones act on the contractile elements of 
the heart and stimulate them by upregulation of beta adrenergic receptors. 
They have a positive inotropic and chronotropic effect. Actions of 
catecholamines are augmented. That is why fibrillation and arrhythmias 
are common in hyperthyroidism. It can also precipitate angina. Blood 
pressure particularly systolic is often raised. Myocardial oxygen 
consumption can be markedly reduced by induction of hypothyroidism. 
Nervous system: 
It act on respiratory centre of brain and maintain the normal 
hypoxic and hypercapnic drive .Mental retardation is the hallmark of 
cretinism. Sluggishness and other behavioural features are seen in 
myxedema whereas tremors, anxiety and hyperreflexia are seen in 
hyperthyroidism. 
Skeletal muscle: 
Thyroid hormones increase the protein turnover and speed of 
muscle contraction and relaxation. Myxedema is characterised by flabby 
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and weak muscles while thyrotoxicosis causes an increase in muscle tone, 
tremor and weakness due to myopathy. 
Gastro intestinal system: 
Thyroid hormones increase gastric motility. Hypothyroid patients 
are often constipated while diarrhea occurs in hyperthyroidism. 
Kidneys 
They have no effect in euthyroid individuals but cause diuresis 
when myxedematous patients are treated with them. 
Haemopoiesis: 
Anaemia occurs in hypothyroid individuals, thus it is proven that 
T4 plays a role in erythropoiesis. 
Reproduction: 
Oligomenorrhoea and subfertility/infertility is known to occur in 
women with hypothyroidism. Normal functioning of the thyroid gland is 
essential for maintenance of pregnancy and lactation. 
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Thyroid changes in Pregnancy: 
Anatomically, the thyroid gland  undergo moderate enlargement 
which is caused by glandular hyperplasia and increased vascularity 
during pregnancy. Mean thyroid  volume increased from 12 ml in first 
trimester to 15 ml at delivery. Total volume of is inversely proportional to 
serum thyrotropin concentration, (so any goiter should be investigated) 
normal pregnancy does not cause  significant thyromegaly. 
Several alteration in thyroid physiology and function during 
pregnancy. In 1
st
  trimester–TBG  increase, reach their zenith at about 
20wks and stabilize at double baseline value for the remainder of the 
pregnancy. 
Increased TBG–higher hepatic synthesis due to estrogen 
(linderberg et al 1974) and lower metabolism rate of TBG sialylation and 
glycosylation and reduced renal clearance(Ain et al 1987) Effect of 
increased TBG due to increased binding of T4 to TBG (Robbins  & 
Nelson 1958)  so Total serum T3 and T4are increased. Biologically active 
free T4are slightly increased and peak along with hCG. Total T4 sharply 
increasing  between6 and 9 wks and reaches plateau at 18 wks. (Glinoer 
et al 1990) 
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Thyroid hormone is derived from iodination of tyrosine residues in 
thyroglobulin to form mono or di iodo tyrosine which are then coupled to 
form T4 and T3. 
Role of deiodinase: 
Free T4 is metabolized in the tissues to the active form free T3 by 
three deiodinase enzymes. The tissues have different rates of free T3 
production and uptake according to the presence of the deiodinase 
enzymes. 
Type 1 – liver,  kidney, thyroid and pituitary-fT3 formation-activity 
 low in fetus. 
Type 2- CNS and pituitary-supply fT3 to the brain 
Type3-  Brain and reproductive tissues-inactivates both fT3 and fT4. 
Only D2 and D3 have been detected in placental tissue.D2-
providing the placenta with supply of fT3 and D3 
maintaining equilibrium. 
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During normal pregnancy, the maternal thyroid hormone 
production increased more than 50%. 
First-Following conception, estrogen concentrations increase 
markedly (lindberg et al 1974) leading to increased production of TBG. 
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The increased binding of thyroid hormone together with its 
increased metabolism by the placenta, developing fetus utilizes the 
maternal TH, increased distribution volume of T4 leads to a greater 
requirement for thyroid hormone production in order to maintain free T4 
levels. Total T4 levels are above the normal non pregnant levels.   
Women who have borderline iodine deficiency may be unable to meet 
this increased demand resulting in reduction in thyroid hormone product. 
So HCG has weak TSH like activity. 
In early pregnancy Serum thyrotropin (TSH) level is decreased 
because of thyroid stimulation from the weak TSH effects of HCG. So 
there is also a slight increase in free T4 levels. Molar gestation, 
hyperemesis gravidarum or multiple gestation  are conditions associated 
with higher than usual HCG levels. These may result in an exaggerated 
stimulation of the thyroid gland and produce transient first-trimester 
thyrotoxicosis. (glinoer 1997) TSH will rebound to normal nonpregnant 
levels once HCG returns to a steady state.  
So there will be a mild decline in free T4 and an increase in TSH 
after the first trimester. But these changes typically remain within the 
reference range. That is why FT4 and TSH levels should be interpreted 
after comparison with specific reference ranges for each trimester 
31 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TSH LEVEL IN PREGNANCY 
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Cut off values for TSH in pregnancy: 
Non pregnant  TSH reference range are unreliable in pregnancy 
due to physiological changes of thyroid.- suppressive effect of increasing 
thyroxin and increased TSH excretion, TSH is kept at its lowest minimal 
level or can even go below normal range. 
Trimester specific values as per ATA2011,ES2012 and USPSTF 
GUIDELINES. 
TRIMESTER TSH(miu/dl) fT4(ng/dl) 
1 trimester 0.1-2.5 0.8-1.2 
2 trimester 0.2-3 0.6-1.0 
3 trimester 0.3-3 0.5-0.8 
 
Glioner et al –S TSH >2miu/ml and TPO Ab >1250u/ml before 20 
weeks predict the occurrence of hypothyroid in later trimester of 
pregnancy 
 
 
Thyroid physiology in the fetus and neonate: 
Development of brain, lung and bone in the fetus is absolutely 
dependent on maternal thyroid hormone. 
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The human fetal thyroid metabolically inactive until 9 and 12 wks, 
starts to concentrate iodine at 11 wks and  is able to produce TG is 
precursor of TH at 4 week. 
At 18 wks the fetal HPT axis fully developed, mature follicles in 
thyroid gland  was developed and it can start to produce TH of its 
own.(Burrow et al 1994) * TSH levels of the fetus continue to increase 
till 28 weeks after that it reaches a nadir and remains at the  level till 
term. 
Free T4 concentration increases progressively till term and exceed 
maternal levels. Hence, some level of fetal hyperthyroidism exists at 
term. 
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Iodine from T3 & T4 removed by D3placental deiodinase  and 
generating inactive iodothyronines and reverse T3.Large amounts of  T4 
crossing the placenta prevented by it. Another reason for increase in 
iodine demand is increased GFR with an increased urinary clearance of 
iodine. Although the fetal thyroid starts developing by 12 wks of 
gestation, it cannot organify iodine till 20wks of gestation. Till that period 
the maternal T4 is the only form of the hormone that can cross the 
placenta. Deiodinase enzyme in the fetus converts maternal fT4 to T3 in 
brain & other tissues. So the fetal iodine store solely demands on 
maternal intake during this period. 
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In 1
st
 trimester total T4 concentration in fetus is directly related to 
mother T4 concentration T3 level lower  than  rT3. 
rT3 level higher because of D3 in the placenta, which acts as 
barrier and protects the fetus from TH excess(calvo et al  2002)  Fetus has 
high free TH levels due to the lower level of binding protein. 
D2  and D3 activity which ensures them a supply of  fT3 .( burrow 
et al. calvo et al, 1994, 2002) 
T4 is the major fetal thyroid hormones. 
In labour the fetus goes from a state of relative T3 deficiency to 
T3thyrotoxicosis. 
Immediately after  birth the TSH rise rapidly & falls to basal levels 
after 48-72hrs of birth.  Because of that T4 and T3 levels increase and 
reach the peak values by 24-48 hours and 24 hours of age respectively. 
Hyperactivity of thyroid disappear at 3-4 wks above changes occur 
mainly due to TRH surge as a response to rapid neonatal cooling since 
the TSH surge is accompanied by a prolactin surge. These thyroid 
changes are believed to be a protective mechanism against sudden entry 
of cool environment. 
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Subclinical Hypothyroidism: 
By definition, it is a condition in which TSH is elevated ,but FT4 is 
normal. 
Incidence of subclinical hypothyroidism is at least 2.5% .Usually it 
is asymptomatic, but there is evidence autoimmune thyroid disease 
(positive TPOAbs and or TG antibodies) in 50-60%(12) Subclinical 
hypothyroidism was found to be more common in women delivering 
before 32 weeks.(12) 
Pregnancies complicated by subclinical hypothyroidism had a 3 
fold increased risk of developing placental abruption and 2 fold increased 
risk of preterm labour compared to euthyroid women.(22)Gestational 
hypertension also occurred more commonly in these women.(23) 
Even raised maternal TSH (high level of normal) is associated with 
neonatal respiratory distress, miscarriage and preterm delivery(12).The 
likelihood of patients diagnosed as hypothyroids during pregnancy to 
continue to be hypothyroid even after pregnancy depends on the initial 
TSH value. The United States Preventive Services Task force reported 
that nearly almost all patients with an initial TSH >5mIU/ml developed 
overt hypothyroidism within 5 years.(33) 
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Treatment of  subclinical Hypothyroidism: 
According to USPSTF, AACE, COCHRANE REVIEW 
recommands treatment for  pregnant women with SCH. 
HISTORY 
Thyroid hormone replacement was first described by Murray 
in1891 by injecting sheep thyroid extract. 
Purified thyroxine crystals was identified by Edward  calvin 
kendall in 1914. 
Structure of thyroxine was identified by British chemist Harrington 
in 1926. 
Drug of choice is oral levothyroxine ,as it is category  A drug 
Levothyroxine or T4,  normally secreted by the thyroid follicular cell. 
Levothyroxine is the synthetic form of thyroxine 
For therapeutic purposes L thyroxine is superior to lio thyronine 
because of its longer duration of action, it has a long half life 7 days, and 
is partially converted to T3 in the body, resulting in constant 
physiological level  of T3 and T4  
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The only accepted indication for the use of liothyronine is 
myxedema coma where a quick response is essential. 
USPSTF GUIDELINES 
Levothyroxine should be taken on an empty stomach either 30 to 
60 minutes before breakfast or at bedtime, with water at the same time 
each day. 
Patients should avoid taking calcium and iron within 4 hrs of 
thyroxine. Increase in dosage is required during pregnancy.  
2014 European thyroid association guidelines-ETA.  
SCH arising during conception and preconception should be 
treated with levothyroxine.  
Before conception pt on Levothyroxine, 25 50% increase in dosage 
is required during pregnancy. 
Newly diagnosed SCH during pregnancy initiating the treatment 
with following dosage 
TSH<4.2miu/dl             – Levothroxine (T4 )dose-1.20ug/kg/day 
TSH >4.2 to 10 miu/dl   -  Levothyroxine (T4) dose -1.42ug/kg/day 
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It should be started as a low dose  of  12.5ug-25ug,maintenance 
dose should be2 -2.4ug/kg/day. 
TSH level should be monitored every 4-6 wks during first 
trimester, once in second and third trimester, titrate the dose rapidly to 
keep the TSH at a level less than 2.5 IU/ml in the first trimester and less 
than 3 IU/ml in second and third trimesters.  
The association urges physicians to be vigilant in identifying and 
treating women with subclinical thyroid dysfunction before conception. 
 
The Journal of Clinical Endocrinology and Metabolism published 
an Executive Summary which  recommends  thyroxine replacement in 
women with subclinical hypothyroidism. 
The goal of LT4 treatment is to normalize maternal serum TSH 
values within the trimester-specific pregnancy reference range (first 
trimester, 0.1–2.5 mIU/L; second trimester, 0.2–3.0 mIU/L; third 
trimester, 0.3–3.0 mIU/L). Level A-USPSTF 
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2014 ETA GUIDELINES 
Role of Iodine in SCH 
In pregnancy there is about a 50% increase in iodine requirement to 
achieve a dietary intake of 250 ug/day. This increase is due to an 
increased glomerular filtration and renal iodine clearance as well as 
iodine trans placental transfer to the fetus particularly in later gestation. 
The contribution of iodine deficiency to the incidence of SCH is 
variable. 
The Spanish study did show high prevalence of  SCH in iodine 
deficient area in Belgium. 
Iodine prophylaxsis in SCH has not been studied. 
Prevention of endemic goiter and presumably some case of SCH 
can be affected by iodine supplementation. 
According to the WHO ,pregnant  and lactating women should be 
provided with 250 ug /day iodine. this should be taken as in the form of 
potassium iodide. 
Should not exceed 500 ug . 
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The effectiveness and side effects of iodine prophylaxsis together 
with  or without L thyroxine theropy in subclinically hypothyroid women 
should be assessed. 
Complications of sub clinical hypothyroidism in pregnancy: 
Maternal  
 Spontaneous abortion 
 Pregnancy induced hypertension(pre eclampsia, eclampsia) 
 Placental abruption 
 IUGR 
 Oligohydramnios 
 Preterm delivery 
 Fetal distress 
 Low birth weight 
Congenital Hypothyroidism: 
Congenital Hypothyroidism (CH) is one of the most common 
preventable causes of mental retardation. The incidence is 1:4000 
livebirths and the worldwide and the incidence in India is 1:2500-2800 
live births.  
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Thyroid dysgenesis is the commonest cause attributing for the 
majority of cases. CH can be permanent or transient. Maternal cytotoxic 
antibodies and genetic mutations causing inactivation of thyroid receptor 
can be a cause. There is clinical and scientific evidence that 
hypothyroxinemia causes poor neurodevelopment outcome in the 
children of mothers with low thyroxine levels. 
In a study by Morreale de Escobar et al in2004,it was noted that 
thyroid hormone accumulates in the cerebral cortex before 20 weeks.(30) 
Primary evidence of the effect of the deficiency of thyroid 
hormone on cerebral cortex was studied by Lavado-Autric et al in 
2003.(31) 
Defects in thyroid hormone synthesis account for 10% of all cases. 
These can be inherited as autosomal recessive disorders. Pharoah et al did 
a landmark study in 1971 and came to a conclusion that iodine 
supplementation in pregnancy prevented subsequent cretinism. 
Early and aggressive treatment with thyroxine is crucial for infants 
with congenital hypothyroidism. Yet some infants with prompt 
replacement exhibit mild cognitive defects in adolescence.(47) 
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CLINICAL FEATURES OF CONGENITAL HYPOTHYROIDISM 
Untreated severe congenital hypothyroidism leads to irreversible 
growth failure and mental retardation 
 Feeding problems, constipation, growth failure and hoarse cry are 
early symptom. 
 Dry skin and decreased growth of nails and hair; delayed tooth 
eruption are delayed symptoms 
 Closure of anterior and posterior fontanellesis delayed 
 Cardiomegaly may be present 
The other clinical features are broad, flat nose, 
pseudohypertelorism, puffy, myxedematous facies, large, protruding 
tongue, prolonged neonatal jaundice, protuberant abdomen, umbilical 
hernia. 
Thyroid antibodies: 
indicate the underlying disorder. Antithyroglobulin, antimicrosomal and 
thyroid stimulating immunoglobulin are the thyroid antibodies. 
Approximately 80% of patients with Hashimoto’s thyroiditis have raised 
thyroid antibody levels. 
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 Thyroid peroxidase (TPO)antibodies and Anti Thyroglobulin (TG) 
antibodies are associate with pregnancy complications. There are 
studies to show that euthyroid women with recurrent miscarriages 
and preterm birth were found to have antibodies to either TPO or 
TG.TPO antibodies have also been implicated in the development 
of postpartum thyroiditis. 
 Association between auto immune thyroiditis and adverse obstetric 
outcome independent of thyroid function has also been proven in 
another prospective study where euthyroid TPO antibody positive 
women who received thyroxine supplementation in early 
pregnancy had a reduced rate of miscarriage and preterm delivery 
rate(12) 
 Pregnant women with TPO antibodies were found to have a three 
times more chances of placental abruption when compared with 
antibody negative controls in a study by Abbassi-Ghanavati et al in 
2010. 
 Pop et al revealed decrease in the intelligent quotient of children 
aged 5 years whose mothers were TPO antibody positive at 32 
weeks of gestation even though they were actually euthyroid.(4) 
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 Some thyroid autoantibodies cross the placenta causing fetal 
thyroid dysfunction. But maternal Hashimoto thyroiditis is not 
typically found to be associated with fetal thyroid abnormalities. 
 Brown and co-workers in 1996 did a study on over one million 
babies and found that only 1 in 180,000 neonates born to mothers 
with Hashimotos thyroiditis had thyroid dysfunction. (46) stagnaro 
green and glinoer studies reported TPO Ab positive women had 
high incidence miscarriage and preterm labour.   
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Screening for thyroid dysfunction during pregnancy: 
For universal screening to be recommended for a disease, 
 The incidence of the disease should be high enough to warrant 
screening. 
 The screening needs to be as cost effective as possible 
 There should be substantiative evidence that adverse outcomes are 
associated with the  disease. 
 There should also be evidence that intervention improves 
outcomes. 
The journal of clinical endocrinology and metabolism adopted a 
clinical practice guideline in 2007 which recommended screening 
among the following high risk women(27) 
a)  Women with a previous history of hyper /hypo thyroid disease / 
thyroid ectomy/goitre 
b)  Women with family history of thyroid dysfunction 
c)  Women with symptoms/signs suggestive of thyroid dysfunction 
d)  Women with autoimmune diseases like Type 1 DM 
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e)  Women with a history of infertility 
f)  Women with history of head and neck irradiation 
g)  Women with history of recurrent miscarriages or preterm 
deliveries. 
According to the ACOG Committee Opinion no.381(oct 2007) also 
thyroid screening in pregnancy should be carried out only on 
symptomatic women/those with a history of thyroid disease or other 
medical illnesses that may be associated with thyroid disease 
(eg:diabetes) 
In a study by Bijay Vaidya et al published in JCEM in 2007, they 
found that thyroid function testing of only high risk women would miss 
about 1/3rd of women with overt/subclinical hypothyroidism.(21) 
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AIMS OF THE STUDY 
Primary Aim: 
To assess the benefits and pregnancy outcome in promptly 
diagnosed and adequately treated antenatal hypothyroid women. 
Secondary Aims: 
To assess whether unfavourable pregnancy outcome and 
complications are more among the antenatal women who are diagnosed 
late in pregnancy and hence inadequately treated. 
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MATERIALS AND METHODS 
To measure pregnancy outcomes in all the study subjects, all 
antenatal women in their first trimester (first booking) or if they have 
their first visit only in second and third trimester will be screened with 
serum TSH. If TSH is more than 3miu/ml, they will be started on 
treatment after doing an FT4.They will be monitored to see if their 
treatment is adequate by repeating a serum TSH again in 2nd and 3rd 
trimesters. These women will be followed up till term and monitored for 
any complications. Finally, they will be analysed to see if there is a 
significant increase in complications in the antenatal women who were 
diagnosed and started on treatment late and whether these complications 
could have been avoided if they were to be started on treatment early in 
the course of pregnancy. 
Inclusion Criteria: 
a)  All first and second trimester antenatal women with singleton 
gestation which will includes, family history of hypothyroid, auto 
immune disease. History of treated PCOD, RPL, miscarriage, 
presence of TPO Ab, Type 1 Diabetes. 
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Exclusion Criteria: 
 Multiple gestation 
 Overt hypothyroidism 
 Thyroidectomy 
USPSTF 2011 
TSH is the more accurate indication of thyroid status in pregnancy 
than any other ( f T4,thyroid Ab) 
ESTIMATION OF TSH 
Method 
Solid Phase Two-Site Immuno Rado Metric Assay (IRMA) with 
IRMAK-9 kit, BRIT, Mumbai. 
Results 
Normal range of TSH was taken as 0.17 – 3 μU/ml. (Trimester 
Specific)  
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ESTIMATION OF FREE T4 
Method 
RIA (Radio Immuno Assay) – IMMUNOTECH  
Results 
Normal range of Free T4 was taken as 0.8 -1.7 ng/dl (Trimester 
Specific) 
ALEXANDER recommends TPO Ab screening in SCH 
ESTIMATION OF TPO Ab 
Method 
Chemi luminescent immune assay 
Results 
Positive >34IU/ML 
Negative<34IU/ML 
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STATISTICAL METHOD 
The statistical package which was used for doing the analysis was 
SPSS 16.00 version. Raw data were analysed using cross tabulations, Chi 
square test and p value. 
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Age in years
> 3026-3021-2518-20
Co
un
t
300
200
100
0
Sub clinical
Yes
No
OBSERVATION AND RESULTS 
AGE DISTRIBUTION 
 
Age in years 
Number Percentage 
 
Eu TH 
 
SCH 
 
Eu TH 
 
SCH 
18-20yrs 3 0 0.6  
21-25 yrs 250 7 53.2  
26-30yrs 195 18 41.5  
>30yrs 22 5 4.7  
 
 
Higher incidence of SCH in26-30 yrs of age 
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Age in years
> 30
26-30
21-25
 
SCREENING AT TRIMESTER 
 
 
TRIMESTER NUMBER PERCENTAGE 
 EuTH SCH EuTH SCH 
1 256 17 54.5% 56.7% 
2 139 8 29.6% 26.7% 
3 75 5 16% 16.6% 
 
 
More than 55 %women screened at 1
st
 trimester in my study. 
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TSH AT DIAGNOSIS OF SCH 
 
 
TRIMESTER 
 
TSH 
LEVEL 
  
2.5 -3uiu/l 3-3.5 >3.5-5 >5 -10 
 No             
% 
No               
% 
No     
% 
No             
% 
1 1             
5.9% 
3           
17.6% 
11    
 64% 
2     
11.8% 
2 - - 7           
87.5% 
1       
12.5% 
3 - - 5           
100% 
- 
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Trimester
321
C
o
u
n
t
12
10
8
6
4
2
0
TSH level
2.5-3.0
3.0-3.5
3.5-5.0
5.0-10
 
 
 
Most of the SCH women TSH range 3.5 -5 miu/dl 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
59 
 
Treatment
No
Yes
ADEQUATE AND INADEQUATE TREATMENT 
 
 
TREATMENT NUMBER PERCENTAGE 
Adequate 13 43.3% 
Inadequate 17 56.7% 
Total 30 100 
 
 
13 women were adequately treated  in my study. 
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PREVALENCE OF PREECLAMPSIA IN EuTH AND SCH 
 
 
Pre Eclampsia Number Percentage 
 EuTH  SCH E uTH SCH 
Present  16 3 3.4 % 9% 
Absent  454 27 96.6% 91% 
 470  30 100 100 
 
 
 
The incidence of preeclampsia in euthyroid women was  
3.4% and 9% in SCH women. 
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PREVALENCE OF GHTN IN EuTH AND SCH 
 
 
 NUMBER PERCENTAGE 
GHTN EuTH SCH EuTH SCH 
Present 23 3 4.8% 10% 
Absent 457 27 95.2% 90% 
Total 470 30 100 100 
 
The prevalence of GHTN in euthyroid women was 
4.8% and 10% in SCH. 
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PREVALENCE OF GDM IN  Eu TH AND SCH 
 
GDM NUMBER PERCENTAGE 
 EuTH SCH EuTH SCH 
Present 63 5 13.3% 16.6% 
Absent 407 25 86.7% 84.4% 
 470 30 100 100 
 
 
The prevalence of GDM in euthyroid and SCH 
women were 13.3%.vs16.6% 
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PREVALENCE OF IUGR IN EuTH AND SCH 
 
 
IUGR NUMBER PERCENTAGE 
 EuTH SCH EuTH SCH 
Present 21 2 4.4% 6.6% 
Absent 449 28 95.6% 93.4% 
 470 30 100 100 
 
 
The prevalence of IUGR in euthyroid was 4.4% and 6.6% in SCH. 
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PREVALENCE OF PRETERM IN EuTH AND SCH 
 
 
PRETERM NUMBER PERCENTAGE P value 
 E uTH SCH Eu TH SCH  
Present 17 4 3.6% 13.3% .031 
Absent 453 26 96.4% 86.7%  
 470 30 100 100  
 
 
The prevalence of  preterm labour  in euhyroid was 
3.6% and 13.3% in SCH. 
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PREVALENCE OF LOW BIRTH WEIGHT IN EuTH AND SCH 
 
 
LOW BIRTH WT 
NUMBER PERCENTAGE 
P value Eu  
TH 
SCH Eu TH SCH 
Present 19 5 4.04% 23.5% .010 
Absent 464 25 95.96% 76.5%  
 470 30 100 100  
 
The prevalence of low birth weight in euthyroid women 
was 4.04% and 23.5% in SCH. 
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PREVALENCE OF LOW APGAR  IN  EuTH  AND  SCH 
 
 
 
LOW APGAR 
NUMBER PERCENTAGE 
P Value Eu 
TH 
SCH Eu TH SCH 
6 2 4 0.4% 13.3%  
7 464 26 98.8% 86.7% .000 
8 4 0 0.8% 0  
Total 470 30 100 100  
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The prevalence of low apgar in euthyroid women 
was  0.4% and 13.3% in SCH 
 
 
 
 
 
  
Low Apgar 
8 7 6 
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PREVALENCE OF NICU CARE IN EuTH AND SCH 
 
 
NICU CARE 
NUMBER PERCENTAGE 
 
Eu TH SCH Eu TH SCH 
Present 16 5 3.4% 16.6% .006 
Absent 454 25 96.6% 83.4%  
 470 30 100 100  
 
The prevalence of NICU Care in euthyroid status 
was 3.4% and 16.6%. 
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PREVALENCE OF RDS IN Eu TH AND SCH 
 
 
RDS Number Percentage  
 
Eu  
TH 
SCH Eu  TH SCH  
Present 11 2 2.3% 6.6%  
Absent 459 28 97.7% 93.4% .180 
 470 30 100 100  
 
 
The prevalence of RDS in euthyroid was 2.3% and 6.6% in SCH. 
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TPO Ab
Negative
Positive
 
PREVALENCE OF TPO Ab POSITIVITY  IN SCH 
 
 
TPO Ab Number Percentage 
Present 5 16.7% 
Absent 25 83.3% 
Total 30 100 
 
 
 
Among the 30 SCH women, TPO Ab Positivity was 16.7%. 
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DISCUSSION 
Prevalence of subclinical hypothyroidism during pregnancy 
and its maternal and fetal outcomes study was conducted in Govt. 
R.S.R.M Lying in hospital from  2015 to  2016. 
In this prospective study 500 women were enrolled .All subjects 
were screened observed and gave birth at the hospital .Thyroid function 
was tested at the first antenatal visit in Stanley hospital. Among  500 
,54.5 % were tested in first trimester, 29.6  % were tested in  second 
trimester and 16 % were tested in third trimester. Information about the 
following demographic and clinical charecterstic were collected through  
proforma. 
         Fasting blood sample were collected in the morning from all 
subjects Serum TSH and ft4 concentration were measured by fully 
automated chemiluminescense immunoassay. The assessment of thyroid 
function based on the following trimester specific TSH and  fT4according 
to the USPSTF Trimester specific values as per ATA2011, ES2012 and 
USPSTF GUIDELINES: 
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TRIMESTER TSH(miu/dl) fT4(ng/dl) 
1 trimester 0.1-2.5 0.8-1.2 
2 trimester 0.2-3 0.6-1.0 
3 trimester 0.3-3 0.5-0.8 
 
SCH defined as exceeding trimester specific TSH concentration 
and normal fT4. 
Euthyroid defined as pregnant women with normal TSH and fT4 
were considered euthyroid and served as control subjects. 
All subject underwent regular antenatal checkup  and delivered at 
govt. RSRM hospital. 
         The following maternal outcomes were diagnosed based on 
guidelines and documented . 
GHTN was defined as SBP >140 mmhg and/ or DBP> 90mmhg 
after 20 weeks of pregnancy, with no previous history of hypertension, 
including preeclampsia.  
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Preeclampsia was defined as persistent elevated blood pressure  
with proteinuria. 
GDM was defined as /or >140 mg/dl at 2 hr after 100mg OGCT. 
Preterm delivery defined as a delivery occurring between 28 and 37 
weeks of gestation. 
The following perinatal outcomes were assessed documented. 
IUGR was defined as an estimated fetal weight below the 10
th
 percentile 
for gestation.  
Fetal distress was defined as fetal heart rate 120bpm or160bpm 
presence of meconium .LBW was defined as live birth weight 2500 g. 
RDS defined as ventilator support>24 hrs. 
In this  study ,  500  pregnant  women were screened out this 30 
women was diagnosed as SCH. In our study prevalence of subclinical 
hypothyroidism is 6% Pregnant women with SCH referred to 
endocrinology OP at Stanley hospital to get adequate dose of L T4. They 
should  be  given treatment  when TSH is above trimester specific values. 
Patients with TSH values between 3-5mIU/ml were started on a 
dose of 25microgram and those with levels from 5-10mIU/ml were given  
50microgram.  
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Based on whether they were started on treatment before 10 weeks 
and given prompt dosage titration, they were grouped as those receiving 
adequate treatment and inadequate treatment.  
TSH levels were repeated for these patients 4-6 weeks after 
initiating the treatment or atleast in each trimester and thyroxine dosage 
titrated according to TSH.   
A patient was considered to have received adequate treatment if the 
repeat TSH values were less than 3 mIU/ml Both the groups were 
followed till delivery and closely observed for the development of 
complications. 
Among 30 SCH women, 13were adequately treated and 17  in 
adequately treated.  Those were belongs to inadequately treated group 
more prone for  both maternal and perinatal adverse outcomes. 
Maternal outcomes in the euthyroid and indequately treated 
subclinical hypothyroidism group; 
In our study more  incidence of GHTN ,pre eclampsia, preterm 
delivery in SCH compared to euthyroid women.(4.8 v 10 %, 3.4% 
v9%,3.6 v13.3 %) which was similar to the outcomes of  studies done by 
Wilson K L Casey B M et al2007,  Lieng mio chen et al 2014. 
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Studies of Manssota et al showed women with SCH had high 
incidence of pre eclampsia, and GHTN.  
Similarly studies of Kharb et al. 
Thyroid hormone have an effect on cardiovascular physiology and 
blood pressure regulation which are mediated by various molecular 
genomic mechanism that cause ventricular remodeling. 
 Studies have proven that thyroid hormone causes endothelial 
dysfunction, which characterised by decreased production of  NO.  
It causes impaired vasorelaxation 
Studies have also reported the altered function of liver and kidney 
during pre eclampsia causes decreased peripheral conversion of T4-T3.I t 
causes T3 hypothyroxiemia and increased TSH levels. 
Loss of protein also causes hypothyroxiemia. 
Studies of wang et al and stagnaro green et al showed increased 
risk of preterm labour in pregnant women with SCH. Studies of cleary 
goldmann showed similar report. 
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IUGR  
IUGR  was  not significantly high in SCH compared to euthyroid. 
Studies of Idris et al, sahu et al and liang miao et al concluded high 
prevalence of iugr in women with SCH. 
Studies of saki et al, pavaranaga et al showed high incidence of 
IUGR in women with SCH 13.7 %7.7% respectively. 
Thyroid hormone is essential for growth and development of  all 
vital organs. hypothyroid have negative effect on pituitary thyroid axsis 
of newborn and  interferes with normal vascular responsiveness and 
cardiovascular homeostasis of the fetus. 
GDM 
IN our study high prevalence of gdm 16.6% in women with SCH 
compared to 13.6% in euthyroid. 
Studies of tudela et al showed 1,9-4.9% of women with SCH had 
GDM.  
Studies of oliveria. agarwl etal, karkosta et al. Tizzo etal showed 
16%,20.2%8.8% 10% of women with SCH  developed GDM. 
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Studies of maratou et al has shown decreased rate of insulin 
stimulated glucose transport inside cells of hypothyroid women. 
Increased insulin resistance was found in SCH women.   
In our study, high incidence of Low birth weight(23.5% vs4.04%)p 
value of .oo1, low apgar at 5 min (13.3%vs1.4%) pvalue of .001, NICU 
admission (16.6% vs3.4%) p value of .001  in SCH group than euthyroid 
which was comparatively similar to the outcomes of studies done by 
Abalovich et al,Liang mio chen et al2014, zhongu fu et al2015 and  
J clinical endocrine metab 20 11 SCH has increase risk of fetal distress 
,low birth weight, low apgar, nicu care and RDS. 
In our study TPO Ab positivity about 16.7% in SCH group. which 
was similar to studies done by Bhattacuryya Rmukherjee  et al 2012,Taka 
mastu et al. 
SCH with TPO Ab positive will develop overt hypothyroidism 
within 2 yrs of delivery.  
In our study SCH diagnosed about 56.7% in first trimester, 26.7%  
in second trimester and 16.6% in third trimester. 
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In our study 2 miscarriage in inadequately treated group.  
In our study 47%  of  inadequately treated SCH group had high 
incidence of maternal complications than adequately treated group 7.6% 
which was similar to studies of Abolvich et al, negro etal .  
    In our study 32% of inadequately treated SCH group had high 
incidence of perinatal complications than adequately treated group 5% 
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SUMMARY 
This includes 500 pregnant women belongs to 20-35yrs attending 
antenatal visit at R S R M Hospital. 
We was screened at first antenatal visit with serum TSH  and free 
T4 .Out of 500, 30 were diagnosed as subclinical hypothyroidism. In my 
study subclinical hypothyroidism is 6% prevalence, most of the SCH 
pregnant women were in the age group of 25-30yrs. 
In this study, more than56% women screened in first trimester. 
Most of the SCH Women has TSH value in the range of  
3.5-5miu/l. 
 There was 16%TPO Ab positive in women with SCH. There were 
13 women belongs to adequately treated women with subclinical and has 
less incidence of complication than 17 inadequately treated SCH women  
There were significant increased prevalence of about 9% 
Preeclampsia, 10% GHTN, 16.6% of GDM, 13.3% preterm birth 
compared to euthyroid pregnant women. 
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CONCLUSION 
Thyroid hormone is essential for early placental development in 
pregnancy. 
Especially during the first twelve weeks of pregnancy the fetus 
entirely depends upon the maternal thyroid hormone for the normal 
neural and skeletal development. 
Hence early diagnosis and adequate treatment of maternal 
hypothyroidism in pregnancy is essential for decreasing the incidence of 
complications like miscarriage, preeclampsia, GHTN, preterm labour, 
low birth weight, low APGAR, NICU admission which are associated 
with subclinical hypothyroidism. 
In our study 47% of inadequately treated group of subclinical 
hypothyroid women had high incidence of complication than adequately 
treated group 7.6%. 
Inadequately treated group had a 3 fold increased risk of 
developing preeclampsia than treated group. 
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There was no significant increase in the incidence of abortion or 
fetal growth restriction in the inadequately treated group than euthyroid  
in our study. 
The high incidence of GDM in our study is 16.6% than euthyroid 
There was no case of placental abruption in my study group. 
In our study inadequately treated group had high incidence of 
LBW, low APGAR,NICU admission, RDS than adequately treated group. 
Adequately treatment group had significantly reduced incidence of 
perinatal complications 3.5% than32%in inadequately treated group. 
Hence, early screening, diagnosis and treatment will prevent 
maternal and fetal complications and reduces the complication of  
subclinical hypothyroidism in pregnancy. 
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31 1 *RENUKAPARMESWARI 1 30 2 37 3.86 1.00 2 170 1 GDM Anaemia 1 1 2 1 1 1 1 11 1 7 2.80 72 Hrs after birth TFT Normal 1 1 1 1 1 2 1 1 1
37 2 NANDHINI 1 28 1 10 3.10 1.07 2 94 2 Missed abortion 1 4 1 1 1 1 1 1 1 1 2
48 3 *KOKILA 1 29 1 38 5.30 1.04 2 77 1 1 1 1 1 1 1 1 1 7 2.60 72 Hrs after birth TFT  NormalNICU Observation1 1 1 2 1 2 1 1 1
74 5 *SHEELADEVI 1 30 1 36 4.25 1.08 2 91 2 GHTN,MSAF,Fetal distress 1 2 1 2 2 2 2 2 6 2.30 LBW NICU Admission,Low APGAR2 2 1 2 1 2 1 1 2
80 6 *SIVAGAMI 1 26 3 38 3.55 1.00 2 87 2 GHTN,MSAF 1 2 1 1 2 1 1 2 3 6 2.80 2 Stage labour diffculty,low apgar,NICU admission2 1 1 2 1 2 1 1 2
83 7 *CHITRA 1 29 1 37 3.69 0.90 2 119 1 oligo,PCOD, treated,induction of labour1 1 1 2 2 1 1 1 1 7 2.50 72 Hrs TFT WNL 1 1 1 1 1 2 1 1 1
93 8 *LIDYAJABASELVI 1 32 1 38 4.80 1.08 2 88 2 previous lscs GHTN 1 2 1 1 1 1 1 2 7 2.95 72 Hrs TFT WNL 1 1 1 1 1 2 1 1 1
100 9 *TEJASRI 1 28 1 37 5.10 1.01 2 158 2 Oligo,CPD,infertility Rxed,GDM 1 1 2 1 2 1 1 2 2 6 2.60 Low APGAR,NICU Admission 1 1 1 1 1 2 1 1 2
108 10 *YASMINFATHIMA 1 22 2 38 3.50 1.20 2 90 1 1 1 1 1 1 1 1 1 7 2.90 72 hrs TFT WNL 1 1 1 1 1 2 1 1 1
116 11 *REBAKA 1 30 1 38 4.26 1.07 2 110 1 previous lscs 1 1 1 1 1 1 1 1 2 7 2.70 72 Hrs TFT WNL 1 1 1 1 1 2 1 1 1
130 12 *GOWSAR 1 28 1 37 4.80 1.20 2 116 2 Anaemia,Fetal distress 1 1 1 1 1 1 2 1 2 7 2.80 72 Hrs TFT WNL 1 1 1 1 1 2 1 1 2
171 13 *MUNNI 1 30 3 37 3.70 1.03 2 109 2 GHTN 1 2 1 1 1 1 1 1 2 7 2.80 72Hrs TFT WNL 1 1 1 1 1 2 1 1 2
201 14 *ESTHERSHEEBA 1 31 2 38 4.04 1.09 2 112 1 1 1 1 1 1 1 1 1 1 7 2.80 72 hrs TFT WNL 1 1 1 1 1 2 1 1 1
262 15  *GOMATHY /nagaraj 1 24 1 37 4.51 1.10 2 92 1 1 1 1 2 1 1 1 1 1 7 2.80 72 Hrs TFT WNL 1 1 1 1 1 2 1 1 1
280 16 *SANGEETHA/Vetrivel 1 32 3 36 4.70 0.90 1 89 1 1 1 1 1 1 2 2 2 3 6 2.25 Low APGAR,Late preterm,NICU Admission,LBW,RDS2 2 2 2 2 2 1 1 2
290 17 *SHAIDHABANU 1 32 2 37 4.80 1.10 2 82 1 1 1 1 1 1 1 1 1 2 7 2.50 TOF Anomaly baby,NICU admission1 1 2 2 2 2 1 1 1
303 18 *AMSAVENI 1 29 1 39 3.98 1.04 2 88 1 1 1 1 1 1 1 1 1 1 7 3.20 72 Hrs TFT WNL 1 1 1 1 1 2 1 1 1
312 19 *DIVYA/Jeyaseelan 1 29 2 37 4.90 1.10 1 116 2 previous lscs 2 1 1 1 2 2 1 1 2 7 2.40 NICU Admission,LBW 1 2 1 2 1 2 1 1 2
334 20 *SHANTHI/Sivanatham 1 28 1 39 3.65 1.05 2 106 1 1 1 1 1 1 1 1 1 1 7 2.90 72Hrs TFT WNL 1 1 1 1 1 2 1 1 1
357 21 *KALAISELVI 1 28 2 37 3.80 1.00 2 170 1 GDM 2 1 2 1 1 1 1 1 1 7 2.90 NICU Admission 1 1 1 1 1 1 1
394 22 SANGEETHA/Parthiban 1 22 3 37 3.65 O.8 2 85 2 fetal distress 1 1 1 1 1 1 2 1 2 6 2.43 LBW/NICU Admission,low APGAR,RDS,Preterm2 2 2 2 2 2 1 1 2
420 23 ELAKIYIA/Yuraj 1 24 1 37 4.12 1.30 2 93 2 2nd stage delay 1 1 1 1 1 1 1 2 3 7 2.80 NICU  Admission,72 hrs TFT WNL1 1 1 1 1 2 1 1 1
432 24 ANITHA 1 32 2 37 5.30 1.07 1 164 2 Overt GDM,Previous lscs 1 1 2 1 1 1 1 1 2 7 3.50 NICU observation,72hrs TFT WNL1 1 1 1 1 2 1 1 1
446 25 KASTURI 1 30 1 37 3.75 1.00 2 106 2 GHTN 1 2 1 1 1 1 1 1 2 6 2.75 NICU Admission,Low APGAR 2 1 1 2 1 2 1 1 2
455 26 POOVIZHI 1 29 1 38 4.03 1,1 2 87 1 1 1 1 1 1 1 1 1 1 7 3.00 72 Hrs TFT WNL 1 1 1 1 1 2 1 1 1
477 477 KAVITHA/Pannerselvam 1 30 3 37 3.70 0.90 2 110 2 Failed induction,preeclampsia 1 1 1 1 1 1 1 1 2 7 2.80 72Hrs TFT WNL 1 1 1 1 1 2 1 1 2
485 485 REVATHY 1 30 3 35 3.80 1.02 2 98 2 IUGR,Oligo,Preterm 2 1 1 1 2 1 2 1 7 2.40 LBW,Late Preterm 1 2 2 1 1 2 1 1 2
489 29 SONIYA 1 25 1 33 3.90 1.14 1 93 2 preterm 1 2 1 2 2 2 1 1 1 7 2.10 NICU Admission,LBW,Preterm 1 2 2 2 1 2 1 1 2
499 499 VAIDHIGEI 1 24 1 10 3.70 1.03 1 102 2 1 2 4 1 1 1 1 1 1 1 1 2
500 500 BHAVANI 1 21 3 33 3.80 1.05 2 94 2 GHTN,ABRUPTIO PLACENTA 1 2 1 2 1 1 2 6 1.90 NICU,PRETERM,LBW,Low APGAR2 2 2 2 1 2 1 1 2
1 1 Meena 2 30 1 39 0.90 1.09 110 1 7 3.00 1
2 2 Elakiya 2 26 1 37 2.90 1.01 78 CPD 2 7 2.90
3 3 Devi 2 28 1 37 2.10 1.00 92 1 8 2.72
4 4 komala 2 30 1 37 1.20 0.90 108 Rh-ve 1 7 3.00
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5 5 saritha 2 23 1 38 2.00 1.01 80 short primi 2 7 3.10
6 6 vaidhagi 2 25 1 38 1.16 1.20 111 1 7 2.85
7 7 Sara 2 27 1 37 2.20 1.10 76 1 7 2.90
8 8 Noorjahan 2 29 2 37 1.40 1.01 93 1 7 2.60
9 9 Vidhya 2 27 1 39 0.80 1.30 101 previous lscs 2 7 3.00
10 10 Mahadevi 2 24 1 37 1.60 1.01 88 1 7 2.70
11 11 divyalakshmi 2 26 1 38 2.10 1.01 79 previous lscs 2 8 2.85
12 12 Bhuvaneswari 2 30 1 37 0.60 1.10 86 1 7 2.90
13 13 vetriselvi 2 26 2 39 1.25 1.03 80 MSAF 2 7 3.50
14 14 Gayathri 2 22 2 37 2.06 1.02 81 1 7 3.00
15 15 Vasanthi 2 25 1 37 2.00 1.60 96 previous lscs 2 7 2.80
16 16 Jayasri 2 32 3 37 0.50 1.01 91 1 7 2.50
17 17 Gandhimathi 2 28 1 37 2.00 1.50 103 2 8 2.67
18 18 Nagamal 2 29 1 38 1.60 1.01 108 1 7 2.90
19 19 Eklisha 2 24 1 37 2.10 1.01 89 1 8 2.88
20 20 Lakshmi 2 25 1 37 1.80 0.90 76 1 7 2.78
21 21 Suryadevi 2 21 2 37 1.40 1.50 72 1 7 2.95
22 22 Dhanalakshmi 2 23 2 36 1.25 1.01 121 2 1 7 2.01 NICU LBW
23 23 Parvathy 2 25 2 37 2.10 1.01 118 GHTN,Failed induction 2 2 7 3.50
24 24 Kaveri 2 24 2 38 2.26 1.05 84 CPD 2 7 3.10
25 25 Monorajitham 2 30 1 37 2.30 1.23 90 previous lscs 2 7 2.75
26 26 Jayanthi 2 29 1 38 1.60 1.04 77 previous lscs 2 7 2.90
27 27 Anitha 2 26 3 38 0.80 1.10 74 Failure to progress 2 7 3.20
28 28 Preethi 2 29 1 37 1.37 1.03 81 2 7 2.90
29 29  sairabanu 2 28 3 37 2.90 1.02 104 Oligo 2 1 7 2.80
30 30 Srisha 2 21 2 37 2.10 1.01 88 1 7 2.70
32 32 Sandhiya 2 27 1 39 1.60 1.30 93 1 7 3.00
33 33 Divyapriya 2 24 1 38 0.90 1.01 90 1 7 3.10
34 34 velankanni 2 27 1 38 1.63 1.06 71 previous lscs 2 7 3.50
35 35 Karthiga 2 23 1 39 0.60 1.70 90 CPD 2 7 3.00
36 kavitha 2 26 2 37 1.02 1.03 100 1 7 2.80
38 Papitha 2 26 1 38 2.00 1.02 91 1 7 2.90
39 Kalyani 2 25 2 37 1.30 1.01 73 GHTTN 2 2 7 2.80
40 Sasikala 2 25 1 38 2.10 1.01 70 1 7 2.80
41 indrani 2 21 3 37 1.72 1.04 105 1 7 2.40
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42 vela 2 22 1 37 1.90 1.01 89 Rh-ve 1 7 2.50
43 Bhavani 2 21 1 37 1.50 1.02 92 1 7 2.70
44 Nancy 2 28 1 38 1.24 0.70 86 previous lscs 2 7 2.70
45 Supriya 2 24 1 37 2.60 1.20 112 2 7 2.90
46 sumathi 2 26 1 38 2.02 1.09 162 Fetal alarm signal GDM 2 2 2 7 3.00
47 jananki 2 29 1 38 1.99 1.01 79 previous lscs 2 7 3.30
49 Devi 2 23 2 38 2.70 1.00 87 Failed induction 2 7 3.20
50 selvi 2 21 1 39 2.00 1.04 91 1 7 2.90
51 Thenmozhi 2 26 1 38 0.70 1.30 103 1 7 3.10
52 4 Nivedha 2 31 3 36 2.70 1.05 111 CPD 2 2 7 2.50
53 Fathima 2 24 1 37 0.50 1.00 106 G HTN 2 1 7 2.76
54 Priyanka 2 23 1 37 1.10 1.02 96 1 7 2.66
55 kowslya 2 23 2 38 0.60 1.80 92 Seizure disorder 1 7 3.00
56 Maleeswari 2 25 1 39 1.30 1.01 90 Fetal distress 2 2 7 3.00
57 Saritha 2 25 2 37 2.20 1.01 88 previous lscs 2 7 2.60
58 Indumathi 2 23 1 39 1.23 1.06 82 1 7 3.20
59 Salmabeevi 2 23 1 38 2.00 1.01 95 previous lscs 2 7 3.00
60 Malathy 2 22 2 37 1.40 1.01 90 previous lscs 2 7 2.90
61 Chandralekha 2 21 2 37 1.80 1.05 89 Anaemia 1 7 2.80
62 Nashima 2 23 1 37 0.80 1.60 81 2 1 7 2.90
63 Kalyani 2 26 1 38 2.36 1.30 84 previous lscs 2 7 3.30
64 raadi 2 30 3 39 2.80 1.20 83 1 7 3.00
65 Kanaga 2 27 2 38 0.40 1.20 91 previous lscs 2 7 3.50
66 Rajeswari 2 27 1 37 2.10 1.07 96 1 7 2.80
67 Venmathi 2 25 1 39 1.85 1.01 90 CPD 2 7 2.90
68 keerthana 2 31 2 37 2.20 1.01 82 1 7 2.60
69 meenatchi 2 27 2 37 1.65 1.09 74 1 7 2.45
70 venkatalakshmi 2 30 2 40 0.80 1.50 78 Failed induction 2 7 2.98
71 sakunthala 2 31 1 38 0.60 1.20 83 1 7 2.75
72 Rani 2 29 1 39 2.38 1.01 154 Rh-ve 2 1 7 2.89
73 Josphine 2 27 1 38 1.90 1.06 90 1 7 2.75
75 Krishma 2 23 3 39 1.56 1.10 95 short primi 2 7 3.40
76 Vishali 2 26 1 39 1.70 1.08 101 1 7 3.00
77 Nasreen 2 25 2 38 2.10 1.03 115 previous lscs 2 7 3.00
78 Amudha 2 28 1 37 2.30 1.06 130 1 7 2.70
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79 ponni 2 21 1 38 1.10 1.01 125 1 7 2.90
81 Mariyam fathima 2 24 2 38 1.72 1.01 98 MSAF 2 7 3.10
82 Gomathi 2 24 1 39 1.60 1.18 90 Fetal distress 2 2 7 3.50
84 Desarani 2 25 1 38 0.60 1.09 89 previous lscs 2 7 2.80
85 kalpana 2 25 1 37 0.80 1.50 145 GDM 1 7 3.00
86 Shalini 2 23 1 39 2.90 1.10 78 2 1 7 2.90
87 Priya 2 22 2 38 2.70 1.20 90 1 7 2.90
88 Revathi 2 24 2 39 2.26 1.06 94 Anaemia 1 7 2.70
89 Nandhini 2 29 1 37 2.10 1.40 106 1 7 2.50
90 Gandhimathi 2 27 1 38 2.33 1.05 82 1 7 2.80
91 Deepa 2 29 2 38 1.30 1.03 90 previous lscs 2 7 3.00
92 Shameema 2 21 3 39 2.21 1.05 76 Non reactive CTG 2 7 3.20
94 Valliammal 2 28 1 39 2.01 1.07 95 1 7 2.80
95 Sathya 2 24 1 37 2.00 1.20 91 1 7 2.75
96 Geethalakshmi 2 27 2 38 2.20 1.09 99 1 7 2.90
97 Rihanna 2 21 2 38 2.10 1.01 80 previous lscs 2 7 3.00
98 Divyabharathi 2 25 2 39 1.30 1.01 79 Failure to progress 2 7 3.10
99 Shanthi 2 25 1 38 1.50 1.07 91 previous lscs 2 7 3.50
101 Archana 2 23 1 39 2.00 1.05 89 1 7 3.00
102 Vasanthi 2 25 2 39 0.80 1.30 103 1 7 2.90
103 Rashikamehar 2 25 1 38 2.30 1.10 120 1 7 2.75
104 Kalarani 2 26 3 37 0.90 1.20 78 1 7 2.60
105 Vidhyarani 2 24 3 37 1.20 1.03 166 previous lscs 2 2 7 2.55
106 Rangeela 2 23 1 38 1.90 1.50 112 CPD 2 7 3.10
107 Suryia 2 23 1 38 2.10 1.06 97 previous lscs 2 7 3.00
109 Kanmani 2 21 1 37 0.70 1.00 94 1 7 2.75
110 Dolphinros 2 27 1 38 1.73 1.30 118 previous lscs 2 7 3.00
111 Annapoorani 2 25 2 38 2.80 1.08 121 previous lscs 2 7 3.20
112 Rajalakshmi 2 22 2 38 1.50 1.00 131 previous lscs 2 7 3.60
113 Dhanalakshmi 2 29 2 37 2.60 1.50 90 Fetaldistress 2 2 7 3.00
114 Jeyasiili 2 28 2 37 2.10 1.20 86 1 7 2.60
115 Gowsiya 2 29 1 38 0.90 1.40 74 previous lscs 2 7 3.00
117 Radha 2 29 1 37 1.30 1.01 105 previous lscs 2 7 3.90
118 Gomathy 2 24 3 39 2.00 1.05 91 Fetal distress 2 2 7 3.40
119 Muthulakshmi 2 26 1 39 1.10 1.01 89 Failed induction 2 7 2.95
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120 Punitha 2 30 2 37 2.30 1.07 85 GHTN,Failed induction 2 2 7 3.00
121 Bhavani 2 28 3 39 2.10 1.02 79 Fetaldistress 2 2 7 3.20
122 Rathi 2 28 1 38 2.00 1.10 107 1 7 2.98
123 Sona 2 27 2 39 0.50 1.00 102  Rh-ve previous LSCS 2 7 3.00
124 Rohnni 2 23 2 39 1.70 1.09 96 CPD 2 7 3.40
125 Shruthi 2 21 3 38 0.80 1.20 92 previous lscs 2 7 3.00
126 Fathima 2 28 1 37 1.20 1.01 88 1 7 3.00
127 Suganya 2 25 1 38 1.70 1.08 82 1 7 2.70
128 Indumathi 2 25 2 37 1.27 1.50 94 1 7 2.70
129 Anusya 2 22 3 37 2.70 1.40 158 2 1 7 2.50
131 Devipriya 2 21 1 37 1.90 1.20 123 1 7 2.90
132 kavitha 2 21 2 37 2.20 1.09 100 Oligo 2 2 7 3.00
133 Sowjana 2 24 3 39 2.40 1.40 90 IUGR 2 2 7 2.50
134 Sabeera 2 25 1 40 2.10 1.10 119 1 7 3.00
135 Shanthi 2 21 2 38 1.80 1.10 99 1 7 2.80
136 Nagalakshmi 2 23 2 38 2.60 1.30 86 previous lscs 2 7 3.70
137 Sudha 2 23 1 39 2.30 1.20 92 1 7 3.00
138 Kowslya 2 24 1 37 2.70 1.10 79 previous lscs 2 7 2.95
139 Reshma 2 25 1 38 0.70 1.00 101 1 7 2.75
140 Bhuvana 2 28 2 37 0.40 1.00 109 Oligo 2 2 7 2.78
141 Sampooranam 2 29 1 37 0.40 1.20 102 1 7 2.67
142 Keerthipriya 2 23 3 39 1.00 1.20 96 1 7 2.45
143 Nishanthini 2 28 2 37 1.84 1.30 83 1 7 2.50
144 Indumathi 2 27 1 37 2.40 1.15 77 1 7 2.80
145 kalpana 2 27 1 38 1.20 1.00 89 previous lscs 2 7 2.80
146 Deepa 2 27 1 37 1.30 1.40 91 previous lscs 2 7 3.00
147 Kalaiselvi 2 32 1 39 2.60 1.20 97 Failed induction 2 7 3.20
148 Nandhini 2 27 2 38 2.02 1.05 104 Failure to progress 2 7 3.50
149 Divya 2 28 1 38 2.30 1.04 113 previous lscs 2 7 3.60
150 Hemalatha 2 26 1 38 1.90 1.04 124 previous lscs 2 7 3.00
151 Soniya 2 24 2 37 2.40 1.10 105 MS AF,Fetal distress 2 2 7 2.80
152 Vadiheyi 2 24 2 37 2.10 1.06 92 Rh-ve 1 7 2.60
153 Munniyammal 2 28 1 37 2.90 1.01 96 1 7 2.90
154 Lavanya 2 25 2 37 2.28 1.01 89 1 7 2.70
155 Srirathi 2 27 1 38 0.60 1.01 86 1 7 2.70
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156 Kusmadavi 2 23 1 37 0.40 1.05 93 GHTN 1 7 2.60
157 Saipriya 2 27 2 38 2.20 1.07 104 1 7 2.80
158 Saranya 2 24 3 37 2.80 1.05 117 1 7 2.40
159 Veni 2 24 1 37 2.10 1.03 121 Anaemia 1 7 2.50
160 Arulselvi 2 26 2 38 1.90 1.02 112 1 7 2.90
161 Arokiyarani 2 22 3 37 1.40 1.02 108 Oligo 2 1 7 2.80
162 Amudha 2 21 2 40 0.70 1.02 89 P0st dated 1 7 2.70
163 Savithr 2 21 1 39 1.60 1.01 78 1 7 3.00
164 Sridevi 2 23 1 38 1.20 1.04 91 previous lscs 2 7 3.20
165 Amirtha 2 25 3 38 0.70 1.09 96 1 7 2.90
166 Manimala 2 27 2 37 1.20 1.20 92 previous lscs 2 7 2.85
167 Sharmila 2 25 3 38 2.50 1.00 89 previous lscs 2 7 3.00
168 Ramya 2 24 1 37 1.40 1.40 85 1 7 2.75
169 Umamaheswari 2 28 2 37 2.60 1.08 84 1 7 2.50
170 Boomadevi 2 28 2 37 0.74 1.23 120 1 7 2.70
172 Thilagam 2 31 1 37 1.07 1.10 98 previous lscs 2 7 2.60
173 Anuradha 2 29 3 37 2.10 1.02 92 1 7 2.70
174 Kannagi 2 26 1 38 1.80 1.00 87 CPD 2 7 3.00
175 Mohanapriya 2 25 1 40 1.70 1.40 91 Failed induction 2 7 3.30
176 Dilshath 2 24 2 38 1.06 1.20 101 previous lscs 2 7 3.20
177 Saraswati 2 23 1 39 1.78 1.10 90 1 7 3.00
178 Ragavee 2 21 2 39 1.34 1.00 111 Failure to progress 2 7 3.40
179 Binny 2 21 1 38 2.24 1.04 108 previous lscs 2 7 3.50
180 Sumithra 2 25 2 38 2.00 1.10 88 previous lscs 2 7 3.80
181 Rekha 2 22 2 37 2.80 1.03 92 1 7 2.75
182 Leela 2 26 1 37 0.90 1.09 94 1 7 2.56
183 Karthiga 2 23 2 37 1.96 1.23 103 1 7 2.70
184 Leena 2 26 3 37 0.50 1.01 86 Anaemia 1 7 2.50
185 Thenmozhi 2 27 1 39 1.00 1.20 79 1 7 2.80
186 Kala 2 29 2 38 1.10 1.02 91 1 7 3.00
187 Sneha 2 31 1 38 2.10 1.30 142 previous lscs 2 7 3.40
188 Sukumari 2 25 1 37 0.50 1.40 132 previous lscs 2 7 3.00
189 Megala 2 27 1 38 2.10 1.20 118 Fetal distress 2 2 7 2.90
190 Rathinam 2 25 1 38 2.40 1.07 109 RHD,Previous lscs 2 7 3.10
191 puspalatha 2 21 2 38 1.20 1.05 95 previous lscs 2 7 2.60
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192 Vaishali 2 23 1 37 1.40 1.03 84 short primi 2 7 2.50
193 Deepika 2 26 1 38 1.20 1.08 109 previous lscs 2 7 2.80
194 Aruna 2 21 1 39 2.50 1.07 111 1 7 3.00
195 Stella 2 25 2 37 1.30 1.09 123 1 7 2.80
196 Geetha 2 25 1 38 2.50 1.30 89 1 7 2.70
197 Uma 2 27 3 37 0.40 1.10 78 Anaemia 1 7 2.30
198 Pradeepa 2 21 1 39 2.00 1.02 94 Primi breech 2 7 2.80
199 Meharsulthana 2 23 1 40 2.20 1.10 90 previous lscs 2 7 3.10
200 Saritha 2 21 1 39 1.60 1.20 107 1 7 3.00
202 Arummaikannu 2 27 1 37 1.40 1.10 105 previous lscs 2 7 3.00
203 Muneeswari 2 25 3 37 2.13 1.09 86 Severe oligo 2 2 7 2.90
204 Padma 2 24 1 38 1.54 1.07 165 CPD 2 2 7 2.89
205 Chinnaponnu 2 25 1 37 1.65 1.01 88 1 7 2.60
206 Pongathai 2 25 1 37 0.60 1.02 74 GHTN 2 1 7 2.70
207 Ambiga 2 23 2 37 2.10 1.40 94 Anaemia 1 7 2.50
208 Baseera 2 23 1 37 2.80 1.06 98 1 7 2.70
209 Mubeena 2 23 2 37 2.30 1.10 106 preclampsia abruption 2 2 7 2.70
210 Hema 2 21 2 37 1.20 1.08 115 previous lscs 2 7 2.70
211 Nithya 2 22 1 38 0.30 1.80 93 1 7 2.90
212 Gowthami 2 24 1 39 2.70 1.07 117 1 7 3.00
213 sulochanna 2 24 1 40 1.49 1.02 112 1 7 3.10
214 Vanja 2 25 3 37 1.35 1.02 132 MSAF,Fetal distress 2 7 3.00
215 Hidha 2 23 2 38 2.31 1.07 85 1 7 2.75
216 Malliga 2 29 1 39 1.63 1.01 90 previous lscs 2 7 2.90
217 Vijalakshmi 2 27 2 37 1.14 1.10 92 1 7 2.80
218 Divya 2 25 1 38 2.13 1.04 79 previous lscs 2 7 3.00
219 Rajalakshmi 2 30 2 37 2.02 1.01 103 1 7 2.50
220 Brindha 2 32 1 38 2.20 1.02 116 previous lscs 2 7 2.80
221 Akila 2 31 1 37 1.32 1.06 121 1 7 2.50
222 Ezhil 2 29 1 37 1.74 1.20 126 short primi 2 7 2.90
223 Pankajam 2 28 1 40 1.63 1.05 102 Primi breech 2 7 3.00
224 Alamelu 2 28 1 39 2.10 1.10 89 1 7 3.10
225 Sinduja 2 27 2 37 1.01 1.50 96 1 7 3.00
226 Poornima 2 25 3 38 0.80 1.25 92 previous lscs 2 7 2.75
227 Valli 2 26 3 38 1.20 1.40 78 previous lscs 2 7 2.80
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228 Sumathi 2 25 1 37 1.88 1.03 90 1 7 2.60
229 Preethi 2 23 1 37 1.56 1.09 104 1 7 2.50
230 Jaya 2 25 2 40 0.70 1.10 87 Failed induction 2 7 2.80
231 Sathya 2 24 2 38 2.20 1.06 120 previous lscs 2 7 3.00
232 Sivaranjani 2 25 1 38 1.40 1.05 110 previous lscs 2 7 3.00
233 Vedhanayagi 2 21 1 37 1.60 1.01 108 previous lscs 2 7 2.90
234 Kalliammal 2 26 1 37 2.00 1.02 98 1 7 2.80
235 Lekha 2 21 1 34 1.50 1.02 93 2 1 7 2.00 NICU
236 Vannathy 2 22 2 38 0.90 1.30 91 1 7 2.70
237 Kalaivani 2 23 2 37 1.10 1.08 89 1 7 2.70
238 Radhika 2 27 3 38 2.10 1.05 160 CPD 2 2 7 3.00
239 Rani 2 29 3 39 1.40 1.07 105 Fetal distress 2 7 3.30
240 Shakila 2 22 2 37 1.92 1.20 102 1 7 3.00
241 venkatalakshmi 2 25 1 38 2.00 1.01 112 previous lscs 2 7 3.25
242 Ponny 2 27 2 37 2.80 1.09 88 1 7 3.10
243 Yavaneswari 2 28 2 38 1.20 1.07 90  Rh-ve previous LSCS 2 7 3.45
244 Sarojini 2 23 1 37 1.50 1.03 95 1 7 2.76
245 Roja 2 23 1 38 2.30 0.90 99 1 7 2.60
246 Chandra 2 22 2 38 0.60 1.20 114 1 7 2.50
247 Bhavani 2 26 1 39 1.39 1.07 100 1 7 2.90
248 Shanu 2 30 2 38 1.10 1.03 94 Failure to progress 2 7 3.00
249 Jaishini 2 29 1 37 1.26 1.01 90 previous lscs 2 7 3.00
250 Elakiyaselvi 2 21 1 39 1.40 1.01 89 1 7 2.90
251 Tamilarasi 2 19 1 40 2.10 1.09 78 1 7 2.80
252 Kamala 2 21 2 37 1.45 1.02 86 Anaemia 1 7 2.50
253 vinodhini 2 27 1 37 1.20 1.01 110 1 7 2.80
254 Punitha 2 27 1 38 1.00 1.05 93 previous lscs 2 7 3.00
255 Ramanidevi 2 24 2 37 2.50 1.07 86 1 7 2.70
256 Ayeshabanu 2 27 1 35 1.80 1.07 82 2 1 7 2.10 NICU
257 Subbulakshmi 2 31 2 38 1.69 1.01 90 previous lscs 2 7 3.00
258 Leelapriya 2 25 1 38 1.23 1.10 102 previous lscs 2 7 3.50
259 Joysmary 2 25 2 39 0.80 1.01 95 Failed induction 2 7 3.20
260 Maniarasi 2 22 1 40 1.75 1.05 107 1 7 3.00
261 Rathinakumari 2 21 3 38 0.50 0.90 96 previous lscs 2 7 2.90
263 vishnupriya 2 25 2 38 1.09 1.01 90 1 7 2.75
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264 Ellamparuthi 2 31 3 37 1.20 1.16 89 preclampsia,failed induction 2 2 7 3.00
265 kalyani 2 23 3 37 0.40 1.63 78 previous lscs 2 7 3.10
266 Srimeenatchi 2 30 2 37 1.34 1.20 83 Anaemia 1 7 2.50
267 Vidhya 2 31 1 39 2.23 1.19 90 1 7 2.80
268 Sasipriya 2 29 1 40 1.27 1.03 94 1 7 2.75
269 Sowmiya 2 25 1 38 1.36 1.27 88 previous lscs 2 7 3.30
270 Santhalakshmi 2 28 2 39 1.72 0.90 96 1 7 3.00
271 Christy 2 27 1 39 1.60 1.08 105 previous lscs 2 7 3.20
272 Vanitha 2 25 1 38 2.40 1.12 86 previous lscs 2 7 3.50
273 Banumathi 2 26 1 37 1.25 1.53 89 1 7 2.90
274 Priyadharshini 2 21 2 39 2.30 1.06 110 1 7 2.75
275 Divya 2 23 3 40 1.84 1.00 104 Fetal distress 2 7 3.00
276 Jammuna 2 27 2 39 2.02 1.17 101 Non reactive CTG 2 7 2.75
277 srikala 2 22 2 39 1.44 1.02 86 1 7 2.65
278 Jayarani 2 21 1 37 2.80 1.11 92 1 7 2.55
279 Astalakshmi 2 24 1 37 1.39 1.09 95 1 7 2.82
281 Ganeswari 2 26 2 34 1.99 1.01 76 2 2 7 1.90 NICU
282 Madhavi 2 28 2 38 1.30 1.26 90 previous lscs 2 7 3.05
283 Shenbagavalli 2 27 1 39 1.34 1.17 94 previous lscs 2 7 3.20
284 Vimala 2 30 1 38 1.00 1.45 92 previous lscs 2 7 3.10
285 Kalpana 2 29 1 40 0.70 1.81 104 1 7 2.90
286 Meena 2 31 1 39 1.47 1.05 101 1 7 2.75
287 Sasikala 2 24 3 37 1.85 1.13 96 Anaemia 1 7 2.60
288 Gayathri 2 29 1 38 1.56 1.68 92 1 7 2.75
289 Rajeswari 2 26 3 37 1.10 1.04 89 GHTN,Failed induction 2 2 7 2.80
291 kavitha 2 24 2 37 1.21 0.80 78 previous lscs 2 7 2.75
292 Muthuselvi 2 26 1 39 1.35 1.02 87 previous lscs 2 7 3.00
293 Sujanthini 2 28 1 40 1.61 1.09 91 CPD 2 7 3.20
294 Padmapriya 2 25 2 40 1.71 1.15 98 Fetal distress 2 7 3.50
295 Amsaveni 2 27 1 39 1.63 1.23 95 1 7 2.90
296 Raseetha 2 30 2 39 1.02 1.50 103 1 7 2.75
297 Vennila 2 27 1 38 2.34 1.03 107 1 7 2.65
298 Nirajannadevi 2 26 2 37 1.41 1.01 94 1 7 2.80
299 Thirumangai 2 29 1 39 2.01 1.07 110 previous lscs 2 7 3.00
300 Kaviya 2 21 3 35 1.89 1.19 89 severe oligo 2 7 2.20
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301 Jothi 2 27 1 39 1.51 1.11 76 1 7 2.75
302 Kalaiarasi 2 27 2 38 1.82 1.20 130 1 7 2.80
304 Kirithiga 2 21 1 40 1.37 1.31 86 1 7 3.00
305 Varshini 2 27 2 37 2.45 0.90 92 Anaemia 1 7 2.00
306 Amalivictoria 2 29 2 37 1.55 1.22 101 IUGR 2 2 7 2.50
307 Thamaraiselvi 2 27 1 38 1.92 1.40 118 2 7 2.90
308 Sunitha 2 29 1 39 2.71 1.01 105 Failure to progress 2 7 2.70
309 Aarthi 2 28 2 38 1.42 1.13 92 previous lscs 2 7 2.80
310 Tamitha 2 33 2 37 0.40 1.00 88 2 7 2.60
311 Poongodi 2 30 1 37 2.03 1.00 109 1 7 2.70
313 Kanimozhi 2 30 1 39 1.53 1.25 104 previous lscs 2 7 3.20
314 Swetha 2 27 1 39 2.00 1.15 92 1 7 3.00
315 Malarvizhi 2 25 1 40 0.40 1.28 88 1 7 3.10
316 Anitha 2 30 3 37 1.09 1.07 79 preclampsia,failed induction 2 2 7 3.00
317 sivasakthi 2 27 1 39 1.62 1.21 84 1 7 3.00
318 Malini 2 25 2 38 1.32 1.03 96 1 7 2.80
319 Rekha 2 26 1 37 1.29 1.40 123 1 7 2.70
320 Latha 2 25 1 37 1.94 1.17 114 1 7 2.70
321 Ranjitha 2 27 2 39 1.30 1.08 92 1 7 2.80
322 Parvathy 2 26 1 37 2.08 1.00 103 1 7 2.50
323 Nalini 2 21 1 38 2.91 1.12 78 1 7 2.50
324 Shiana 2 32 2 38 2.00 1.31 80 2 7 2.80
325 Jothika 2 23 1 39 1.27 1.08 100 1 7 2.70
326 Muthumari 2 25 3 39 1.82 1.05 91 Rh-ve 1 7 2.90
327 Kasthuri 2 24 3 37 1.77 1.04 86 GHTN,Failed induction 2 2 7 2.60
328 Ishwaraya 2 24 2 37 1.20 1.14 79 previous lscs 2 7 3.00
329 Anandhi 2 22 1 38 1.95 1.21 90 1 7 2.80
330 Chitradevi 2 23 1 38 1.45 1.02 94 1 7 3.00
331 Kalpana 2 24 1 39 1.66 1.01 102 previous lscs 2 7 3.00
332 jayasri 2 23 1 38 2.41 1.19 89 previous lscs 2 7 3.40
333 Haripriya 2 21 1 39 2.10 1.15 111 1 7 2.80
335 Seema 2 23 1 40 1.51 1.11 93 1 7 3.00
336 Meera 2 21 1 38 1.55 1.07 104 Seizure disorder 1 7 2.50
337 Saritha 2 21 2 37 1.21 1.10 145 2 1 7 2.70
338 Manimozhi 2 26 2 38 0.80 1.30 126 1 7 2.80
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339 Ambiga 2 22 3 39 1.09 1.06 92 Fetal distress 2 2 7 2.90
340 priyadharshini 2 23 2 40 1.40 1.21 120 CPD 2 7 3.00
341 Akila 2 24 3 37 2.50 1.03 108 previous lscs 2 7 3.00
342 Reshmi 2 27 1 38 1.70 1.09 112 1 7 2.70
343 Anbumalar 2 29 1 39 1.40 1.18 94 short primi 2 7 3.00
344 kalaimathi 2 28 1 38 1.20 1.45 92 previous lscs 2 7 3.00
345 Deepthi 2 27 3 37 1.39 1.01 89 Transverse lie 2 7 2.75
346 Nisha 2 20 1 38 2.00 1.07 76 previous lscs 2 7 3.00
347 Pappathy 2 25 2 40 1.11 1.05 119 1 7 3.10
348 Salomi 2 28 3 37 1.94 1.12 95 1 7 2.60
349 Umadevi 2 23 3 37 1.54 1.00 103 2 1 7 1.80
350 Swathi 2 21 3 37 1.31 1.20 88 1 7 2.50
351 Durga 2 23 1 39 1.68 1.40 90 1 7 2.80
352 Bharathi 2 24 2 37 2.71 1.03 102 preclampsia,failed induction 2 2 7 2.75
353 Hemaakilandeswari 2 28 2 38 1.20 1.07 94 GDM CPD 2 2 7 3.60
354 Radika 2 21 1 38 1.17 1.09 85 previous lscs 2 7 3.50
355 Manimegalai 2 23 1 38 1.28 1.29 88 previous lscs 2 7 3.00
356 Rangeela 2 27 3 37 1.35 1.17 92 severe oligo 2 7 2.20
358 karpagam 2 21 3 37 2.30 0.90 101 1 7 2.70
359 Deni 2 30 2 37 1.19 1.31 117 1 7 2.70
360 shanthi 2 27 1 37 1.22 1.01 120 1 7 2.50
361 Suganya 2 25 3 37 1.90 1.26 86 1 7 2.50
362 Shymala 2 23 2 37 2.04 1.07 90 1 7 2.60
363 Divyabharathi 2 23 3 38 1.71 1.15 94 MSAF,Fetal distress 2 2 7 3.00
364 Ammulu 2 36 2 37 1.08 1.21 105 1 7 2.70
365 Sheeba 2 24 3 37 1.79 1.20 90 1 7 2.75
366 Hafia 2 22 3 37 1.13 1.10 96 1 7 2.50
367 Cyindhiya 2 21 3 37 1.05 1.05 92 1 7 2.50
368 Rahini 2 25 1 39 1.82 1.12 100 1 7 3.00
369 Kalliammal 2 25 2 37 0.50 1.50 86 GHTN 2 1 7 2.80
370 Neela 2 32 1 38 2.27 1.41 79 1 7 2.30
371 Ganga 2 29 1 39 1.25 1.02 82 1 7 2.50
372 Ellammal 2 26 1 37 1.47 1.18 94 1 7 3.00
373 Suba 2 28 1 37 2.39 1.25 107 1 7 2.70
374 Lakshmipriy 2 25 1 38 0.70 1.12 114 1 7 2.80
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375 Kowslya 2 21 1 37 0.80 1.20 148 2 7 2.60
376 Kaveri 2 25 1 37 1.00 1.05 92 1 7 2.50
377 Sangeetha 2 26 1 37 1.18 1.37 88 1 7 2.70
378 Lavanya 2 23 1 38 2.19 1.10 95 1 7 2.60
379 Banupriya 2 31 1 38 1.87 1.21 102 1 7 2.90
380 Jairabanu 2 25 2 38 2.13 1.13 77 previous lscs 2 7 3.00
381 Veena 2 21 3 39 1.36 1.02 91 Primi breech 2 7 3.00
382 Shiba 2 21 3 40 1.29 1.09 85 Failure to progress 2 7 3.20
383 Bhuvaneswari 2 26 3 40 1.50 1.07 101 CPD 2 7 3.00
384 Punitha 2 24 2 38 2.07 1.33 115 previous lscs 2 7 3.00
385 Devi 2 21 1 37 1.70 1.11 121 1 7 2.60
386 Usha 2 23 1 38 2.19 1.00 108 1 7 2.90
387 Monica 2 27 3 37 1.02 1.28 93 severe oligo 2 7 2.70
388 Nithya 2 25 1 38 2.61 1.41 87 1 7 2.80
389 Vanitha 2 30 2 37 1.16 1.08 79 1 7 2.60
390 Loganayagi 2 28 3 37 1.27 1.16 103 1 7 2.50
391 Pramila 2 27 3 37 1.91 1.04 110 1 7 2.40
392 Vanipriya 2 21 2 37 2.03 1.01 95 1 7 2.60
393 Gomathy 2 29 1 39 1.48 1.23 90 Fetal distress 2 7 3.00
395 Vaitheeswari 2 26 1 39 1.05 1.19 88 2 1 7 3.00
396 Ishwaraya 2 23 1 37 2.28 1.20 106 1 7 2.75
397 Tamilselv 2 25 1 38 0.40 1.40 93 1 7 2.90
398 Vijayalakshmi 2 25 2 37 1.10 1.15 90 1 7 2.70
399 Rajaeshwari 2 22 1 39 1.90 1.05 89 1 7 3.00
400 Vidhyavathi 2 24 1 38 2.12 1.10 76 previous lscs 2 7 3.30
401 Mumtaj 2 24 2 37 1.60 1.09 84 1 7 2.50
402 Sandiya 2 28 3 37 1.85 1.06 93 1 7 2.60
403 Saravani 2 26 1 37 1.40 1.21 120 1 7 2.80
404 Revathy 2 30 1 39 2.00 1.25 112 1 7 2.75
405 Hemalatha 2 29 1 40 1.07 1.12 92 1 7 2.80
406 Manjula 2 27 1 38 2.35 1.19 79 1 7 2.70
407 Guntidevi 2 21 1 38 2.09 1.01 85 1 7 2.80
408 Thulasi 2 31 1 37 0.60 1.07 118 1 7 2.60
409 Srividhya 2 27 1 39 1.01 1.12 86 CPD 2 7 3.50
410 Salkabeevi 2 23 2 38 1.20 1.24 79 1 7 2.90
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411 Meentchi 2 28 1 38 1.51 1.10 90 previous lscs 2 7 3.00
412 Kreethana 2 21 3 37 1.72 1.50 96 previous lscs 2 7 2.60
413 Palavi 2 22 2 39 1.66 1.02 89 1 7 3.00
414 Selvi 2 25 1 38 2.01 1.08 78 1 7 2.80
415 Jency 2 23 3 37 1.81 1.00 92 GHTN,Failed induction 2 2 7 2.75
416 Prema 2 26 2 37 1.95 1.11 88 1 7 2.90
417 Bhuvana 2 27 3 37 1.30 1.21 101 Previous lscs 2 7 3.00
418 Pooja 2 29 3 36 1.10 1.03 115 severe oligo 2 2 7 2.50
419 Pusparani 2 31 1 37 0.40 1.05 120 Oligo 2 1 7 3.00
421 Shiana 2 22 2 38 2.12 1.17 76 1 7 2.70
422 Dhanabagium 2 20 3 36 2.50 1.35 84  Oligo 2 2 7 2.50
423 Valarmathi 2 24 3 37 1.90 1.14 90 1 7 2.60
424 Ponni 2 28 2 37 1.25 1.20 102 1 7 2.90
425 Abirami 2 27 1 37 1.33 1.01 94 1 7 2.75
426 Vinitra 2 29 3 37 1.76 1.19 82 IUGR Oligo 2 2 2 7 2.30 LBW/NICU Admission
427 Poomagal 2 24 3 34 1.05 1.23 76 severe eclampsia,unfavor cx 2 2 7 1.90 LBW/NICU Admission
428 Bhavani 2 30 1 38 1.91 1.16 98 previous lscs 2 7 3.00
429 Sameera 2 29 3 37 1.29 1.14 78 1 7 2.50
430 Thenmozhi 2 28 2 38 0.70 1.02 104 1 7 2.90
431 Nishanthini 2 24 2 37 1.20 1.05 92 1 7 2.70
433 poomari 2 27 3 37 1.50 1.12 114 1 7 2.60
434 Mageswari 2 29 1 38 1.21 1.31 96 previous lscs 2 7 3.40
435 velankanni 2 33 3 37 1.00 1.21 89 Preclampsia,oligo 2 2 7 2.50
436 Nagasundari 2 25 2 38 2.62 1.09 78 Fetal alarm signal 2 7 2.90 NICU Observation
437 Pugalenthi 2 24 1 39 1.25 1.01 92 3 7 3.00
438 vasuki 2 29 1 37 1.38 1.18 105 1 7 2.80
439 Medtila 2 27 1 38 1.56 1.10 120 1 7 2.90
440 Porkalai 2 22 2 37 1.80 1.06 82 2 1 7 2.50
441 stella 2 28 1 39 1.71 1.08 78 1 7 3.50
442 Jenthbegam 2 21 1 38 1.51 1.70 84 1 7 2.90
443 Janaki 2 23 1 40 1.66 1.03 93 1 7 3.50
444 Rukmani 2 26 1 37 1.33 1.12 97 1 7 2.80
445 Jancythabetha 2 30 1 38 1.17 1.20 102 previous lscs 2 7 2.80
447 Sujatha 2 26 3 37 1.63 1.00 94 GHTN 2 2 2 7 2.50
448 kalaiselvi 2 23 1 39 2.80 1.19 115 1 7 2.80
N
e
w
.S
N
o
S
n
o
N
A
M
E
S
u
b
_c
li
A
g
e
T
ri
m
e
G
A
T
S
H
F
T
4
T
P
O
A
b
O
G
C
T
T
R
E
A
T
m
a
t_
co
m
P
R
E
 E
C
L
A
M
P
S
IA
G
H
T
N
G
D
M
IU
G
R
O
L
IG
O
P
R
E
T
E
R
M
F
E
T
A
L
 D
IS
T
R
E
S
S
L
A
B
O
U
R
 
C
O
M
P
L
IC
A
T
IO
N
m
o
d
_d
e
li
A
P
G
A
R
b
a
b
y
_w
e
i
fe
t_
co
m
L
O
W
 A
P
G
A
R
L
B
W
P
R
E
T
E
R
M
N
IC
U
R
D
S
T
F
T
D
E
L
A
Y
E
D
 P
A
S
S
A
G
E
 
O
F
 M
E
C
O
N
IU
M
P
R
O
L
O
N
G
E
D
 
N
E
O
N
A
T
A
L
 
JA
U
N
D
IC
E
449 vidhyalakshmi 2 28 1 38 2.32 1.10 109 1 7 2.90
450 vasantha 2 27 1 39 2.08 1.02 107 1 7 3.50
451 karpagavalli 2 29 1 38 1.58 1.01 111 previous lscs 2 7 3.40 NICU
452 Shobana 2 22 2 38 1.21 1.01 108 CPD 2 2 7 2.00
453 Geetha 2 21 1 38 1.85 1.05 105 1 7 3.00
454 Kalaimani 2 25 2 37 0.80 1.15 95 1 7 2.60
456 Sumiya 2 31 1 39 1.20 1.03 79 Failed induction 2 7 3.00
457 Prabha 2 26 1 37 1.40 1.33 112 1 7 2.70
458 Olimathi 2 28 1 38 1.75 1.20 100 previous lscs 2 7 2.70
459 Chitra 2 25 2 37 1.30 1.00 98 GHTN 2 2 7 2.70
460 Yamini 2 27 1 39 1.70 1.09 89 Failure to progress 2 7 3.80
461 Vijaya 2 26 1 38 1.10 1.05 86 previous lscs 2 7 2.90
462 Boopathy 2 25 2 37 1.06 1.14 77 1 7 2.60
463 Jayachitra 2 23 3 37 1.99 1.04 84 Oligo,IUGR 2 2 2 7 2.50 NICU/RDS
464 Karthiga 2 27 1 39 1.52 1.12 90 CPD 2 7 3.20
465 Mala 2 26 1 38 1.33 1.19 94 previous lscs 2 7 3.00
466 Ellamathi 2 25 1 38 1.49 1.07 83 previous lscs 2 7 3.30
467 Divya 2 25 1 38 2.12 1.02 78 previous lscs 2 7 2.90
468 Ramya 2 25 1 38 1.60 1.08 92 1 7 2.80
469 kalyani 2 23 2 37 1.40 1.30 88 1 7 2.70
470 Durga 2 29 3 37 1.70 1.09 98 1 7 2.50
471 Hemavathy 2 30 1 39 2.00 1.16 106 2 7 3.10
472 Malliga 2 28 1 38 1.91 1.31 114 1 7 2.75
473 Rajeshwari 2 23 1 38 1.50 1.29 120 1 7 2.80
474 Sathya 2 21 2 37 2.40 1.03 118 1 7 2.70
475 475 Mahalakshmi 2 22 2 37 2.60 1.11 95 MSAF,Fetal distress 2 7 2.90 NICU/RDS
476 476 Hema 2 25 1 37 2.02 1.23 89 previous lscs 2 2 7 3.00
478 478 Anitha 2 28 1 37 1.85 1.00 85 1 7 2.80
479 479 Saraitha 2 23 2 37 1.39 1.19 94 1 7 2.50
480 480 suganya 2 25 3 37 1.56 1.10 92 CPD 2 7 2.50
481 481 Gomathy 2 23 1 37 2.40 1.02 105 1 7 3.00
482 482 Kavitha 2 22 1 37 2.01 1.01 113 1 7 2.74
483 483 Radhiga 2 27 1 39 1.95 1.22 110 1 7 2.90
484 484 shanthi 2 27 1 38 1.67 1.16 92 2 7 3.10
486 486 Kalpana 2 25 2 37 1.00 1.21 86 Rh-ve 1 7 2.60
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487 487 Suriya 2 23 1 38 0.80 1.31 75 1 7 2.70
488 488 Rani 2 24 1 39 1.90 1.12 88 Failure to progress 2 7 2.95
490 490 Priya 2 27 2 37 1.40 1.09 90 1 7 2.70
491 491 Kasturi 2 23 1 38 2.10 1.05 107 previous lscs 2 7 3.00
492 492 Megala 2 25 1 39 1.24 1.01 91 1 7 2.90
493 493 Divya 2 30 2 37 1.39 1.25 95 1 7 2.70
494 494 Bhavani 2 23 2 37 2.18 1.18 87 1 7 2.60
495 495 Punitha 2 22 3 37 1.19 1.20 79 oligo 2 2 7 2.80
496 496 Sangeetha 2 28 1 39 1.50 1.00 101 1 7 3.00
497 497 Dilshath 2 25 2 37 1.20 1.07 95 1 7 2.50
498 498 Nancy 2 24 2 35 1.80 1.02 105 Cord prolapse 2 7 2.20 NICU
 LIST OF ABBREVATIONS 
TSH   - Thyroid Stimulating Hormone 
T3   - Tri iodo thyronine 
T4   - Tetra iodo thyronine 
HCG   - Human Chorionic Gonadotropin 
Wks   - Weeks 
PIH   - Pregnancy induced hypertension 
IUGR  - Intra uterine growth restriction 
NICU                    new born intensive care unit 
EuTH                    Euthyroid 
SCH                       Subclinical hypothyroidism 
LBW   - Low birth weight 
Rx   - Treatment 
GDM  - Gestational diabetes mellitus 
HTN   - Hypertension 
TPO Ab   - Thyroid peroxidase antibody 
 
